Perfluorohexane sulfonic acid (PFHxS), its salts and PFHxS-related compounds

DRAFT RISK PROFILE

Persistent Organic Pollutants Review Committee

April 2018
# Table of contents

**Executive summary** .................................................................................................................. 3

1. **Introduction** ............................................................................................................................. 5
   1.1 Chemical Identity ....................................................................................................................... 5
   1.2 Conclusion of the POPs Review Committee regarding Annex D information ....................... 7
   1.3 Data sources ............................................................................................................................ 7
   1.4 Status of the chemical under national regulations and international forums ....................... 8

2. **Summary of the information relevant to the risks profile** ...................................................... 8
   2.1 Sources ...................................................................................................................................... 8
      2.1.1 Production, trade, stockpiles ................................................................................................. 8
      2.1.2 Uses ..................................................................................................................................... 10
      2.1.3. Releases to the environment ............................................................................................... 11
   2.2 Environmental fate ................................................................................................................... 12
      2.2.1 Persistence ........................................................................................................................... 12
      2.2.2 Occurrence of PFHxS precursors and degradation ............................................................... 13
      2.2.3 Bioaccumulation and toxicokinetics .................................................................................... 14
      2.2.4 Potential for long-range transport ....................................................................................... 16
   2.3 Exposure ................................................................................................................................... 17
      2.3.1 Environmental levels and trends ........................................................................................ 17
      2.3.2 Human exposure ................................................................................................................ 18
   2.4 Hazard assessment for endpoint of concern ........................................................................... 21
      2.4.1 Toxicity to aquatic organisms and birds .......................................................................... 21
      2.4.2 Toxicity in rodents relevant for humans .......................................................................... 21
      2.4.3 Human epidemiology ......................................................................................................... 23
      2.4.4 Mixture toxicity and combined effects of multiple stressors .......................................... 25

3. **Synthesis of information** ........................................................................................................ 26

4. **Concluding statement** ............................................................................................................ 29

5. **References** .............................................................................................................................. 30
Executive summary

1. The POPs Review Committee at its thirteenth meeting concluded that perfluorohexane sulfonic acid (PFHxS) fulfilled the screening criteria in Annex D and decided that issues related to the inclusion of PFHxS salts and PFHxS-related compounds that potentially degrade to PFHxS should be dealt with in developing the draft risk profile (decision POPRC-13/3). The substances covered in this risk profile include PFHxS (CAS No: 355-46-4), its salts and PFHxS-related compounds, defined as any substances that contain the chemical moiety C₆F₁₅SO₂ as one of their structural elements and that potentially degrade to PFHxS.

2. PFHxS, its salts and PFHxS-related compounds are or have been widely used in fire-fighting foams, as surfactants, in metal plating as well as in cleaning, waxing, polish and other surface treatment products, and/or water- and stain-protective coatings for carpets, paper, leather and textiles, in many cases as a replacement for PFOS. PFHxS is distributed in the environment including in urban cities, rural areas and in regions that produce or use PFHxS or its precursors in the processing or manufacture of commercial products. It is also found in Arctic regions far away from any sources of release. In addition, PFHxS, its salts and related compounds have also been used in per- and poly-fluoroalkyl substances (PFASs) based consumer products. PFHXS are and have been unintentionally produced during the electrochemical fluorination (ECF) processes of other PFASs.

3. Historically, 3M was most likely the main manufacturer of PFHxS, its salts and PFHxS-related compounds with an annual production of about 227 tonnes of the raw material PFHxSF in the US in 1997. Current manufacturers of PFHxS, its salts and PFHxS related compounds include at least one producer in Italy and most likely a number of producers in China. Information in the public domain on current production and historic volumes of PFHxS, its salts and PFHxS-related compounds is very limited.

4. Limited research has been conducted on releases of PFHxS, its salts and PFHxS-related compounds to the environment. In general terms, releases to the environment occur from the production of the raw material (i.e. PFHxSF) and its derivatives (i.e. PFHxS, its salts and PFHxS-related compounds), during the processing, use and disposal, as well as from consumer products containing the derivatives. Release of PFHxS and perfluorohexane sulfonamides (FHxSA) is documented publicly from consumer products by their detection in dust and in wastewater, sludge and leachate from landfills and releases due to use of aqueous film-forming foams (AFFFs) containing PFHxS and PFHxS-related compounds such as FHxSA.

5. PFHxS is persistent in the environment. Numerous studies have reported elevated levels of PFHxS in soil, water and a variety of biota. Contamination with PFHxS is especially apparent in the vicinity of fire-fighting training areas as a result of the historical (and ongoing) use of PFHxS-containing foams. The perfluoroalkyl moiety C₆F₁₅ in general is very resistant to chemical, thermal and biological degradation due to its strong carbon-fluorine (C-F) bonds which make many PFASs, particularly perfluoroalkyl acids such as perfluoroalkyl sulfonic acids (PFSA), very persistent in the environment. Due to the combined hydrophilic and hydrophobic properties as well as the acid dissociation of PFHxS, it is very challenging to experimentally measure logKow of the undissociated acid. Furthermore, the PFHxS ion is relatively water-soluble and it binds to proteins in target organisms. In fish, the substance is not expected to be accumulated by the organism but excreted rather rapidly via the gills, resulting in bioaccumulation factors (BAFs)/bioconcentration factors (BCFs) under the criteria of 5000. Based on the identified protein bioaccumulation mechanism standard BCF/BAF are less meaningful descriptors for bioaccumulation for PFAS including PFHxS. However, biomagnification does occur, with biomagnification factors (BMFs) and trophic magnification factors (TMFs) >1 (BMF range 1.4–373 and TMF range 0.1–4.3) available for PFHxS, including from the organisms in the Arctic food chain. The estimated serum elimination half-life of PFHxS in humans is higher than other PFASs and varies from 5.3 to 35 years.

6. Worldwide monitoring of water, air, sediment and biota at remote locations have detected the presence of PFHxS. At Svalbard, Norway, an annual increase has been observed in PFHxS levels in polar bears most likely due to elevated transport through water and air to the Arctic. Direct transport through ocean currents is likely the main mechanism of transport to remote regions, in addition to air transport of PFHxS and its precursors. PFHxS has been detected in air, snow, meltwater, rainwater and lichen, indicating that air transport of precursors that may degrade to PFHxS locally, has occurred. Furthermore, PFHxS as well as FHxSA have been detected in leachates from landfills receiving waste from many sources, indicating possible uses of PFHxS precursors in consumer products.

7. Exposure of the general population takes place by consumption of food, drinking water, by inhalation of indoor air and respiratory and oral uptake of dust from consumer products containing PFHxS, its salts and PFHxS-related compounds. PFHxS has been detected in human blood and breast milk worldwide, and is together with perfluorooctane sulfonic acid (PFOS), pentadecafluorooctanoic acid (PFOA) and perfluorononanoic acid (PFNA) one of the most frequently detected and predominant PFASs in human blood. The foetus is exposed to PFHxS via the umbilical cord blood and breast milk may be an important source of exposure for the infant. In women post-menarche and males, PFHxS levels increase with age, and in general, the highest levels have been observed in men.
8. In regions where regulations and phase-outs have been implemented, human concentrations of PFOS, PFDS, and PFOA are generally declining, while previously increasing concentrations of PFHxS have begun to level off. However, there are also observations of no decline or increasing levels of PFHxS in the same regions, most often connected to households receiving PFHxS contaminated drinking water, but in a few cases also in individuals that get their exposure from unknown sources. Limited data are available on levels and trends of PFHxS in humans in Asia where production continued after the 3M phase out.

9. PFHxS affects liver function, lipid and lipoprotein metabolism and activates the peroxisome proliferating receptor (PPAR)-alpha. In studies on rodents, increased liver weight as well as marked hepatocellular hypertrophy, steatosis and necrosis have been observed. Furthermore, alterations in serum cholesterol, lipoproteins and triglycerides have been observed both in rodents and humans after PFHxS exposure. Effects on reproduction (decreased litter size and fertility index) have been observed in mice after PFHxS exposure. PFHxS binds to the thyroid transport protein, and has been associated with changes in serum thyroid hormones across species. Some evidence suggests that exposure to PFHxS might affect the developing brain and immune system.

10. PFHxS is ubiquitous in environmental compartments such as surface water, deep-sea water, drinking water, waste-water treatment plants and leachates from landfills, sediment, groundwater, soil, the atmosphere, dust, biota (including wildlife), and humans globally. PFHxS is persistent, bioaccumulative, toxic to animals including humans and transported to locations far from its production and use. Therefore, it is concluded that PFHxS, its salts and PFHxS-related compounds are likely, as a result of their long-range environmental transport, to lead to adverse human health and/or environmental effects such that global action is warranted.
1. Introduction

11. In May 2017, Norway submitted a proposal to list perfluorohexane sulfonic acid (PFHxS), its salts and related compounds in Annexes A, B and/or C to the Convention. The proposal (UNEP/POPS/POPRC.13/4) was submitted in accordance with Article 8 of the Convention, and reviewed by the POPs Review Committee (POPRC) at its thirteenth meeting in October 2017.

12. PFHxS, its salts and PFHxS-related compounds belong to the per- and poly-fluoroalkyl substances (PFAS) group. PFASs consist of carbon chains of different chain length, where the hydrogen atoms are completely (perfluorinated) or partly (polyfluorinated) substituted by fluorine atoms (Buck et al., 2011). The very stable bond between carbon and fluorine is only breakable with high energy input (see also 2.2.1 Persistence). Therefore, substances like PFHxS are not degradable in the environment. However, PFHxS salts and other PFHxS-related compounds can degrade to PFHxS under environmental conditions and are therefore known as precursors. A number of PFHxS-related substances including some polymers, have been identified (See section 2.1.1 and 2.1.2; Norwegian Environment Agency, 2017a, M-792/2017) and included in the proposal submitted by Norway (UNEP/POPS/POPRC.13/4).

13. The read-across approach has been applied mainly for the persistent criteria in this document. Guidance from the European Chemical Agency (ECHA, 2017c) and from the Organisation for Economic Co-operation and Development (OECD, 2014) has been used in terms of the definition of grouping of substances and use of the approach. In general, the read-across approach can be applied for substances of which physico-chemical and/or toxicological and/or ecotoxicological properties are likely to be similar or follow a regular pattern as a result of structural similarity. PFHxS belong to a group of PFASs of which several similar substances already have been assessed with respect to their POP- or persistent, bioaccumulation and toxicity properties. The substances in this group have a highly similar chemical structure with a perfluorinated carbon chain and a terminal acid group, sulphonic acid (PFSA) or carboxylic acid (PFCA), which justifies the use of read-across. It is clearly stated in the present document when the read-across approach has been applied.

1.1 Chemical Identity

14. The proposed compounds included in the nomination of PFHxS, its salts and PFHxS-related compounds were defined in document UNEP/POPS/POPRC.13/4 and in decision POPRC-13/3 (UNEP/POPS/POPRC.13/7). A non-exhaustive list of substances including CAS numbers are contained in the information document (UNEP/POPS/POPRC.14/INF/[…] ). In line with decision POPRC-13/3, the following apply:

(a) Perfluorohexane sulfonic acid (CAS No: 355-46-4, PFHxS);

(b) Any substance that contains the chemical moiety C₆F₁₃SO₂⁻ as one of its structural elements and that potentially degrades to PFHxS.

15. A number of chemicals are included in the group of PFHxS, its salts and PFHxS-related compounds and some examples are given in Figure 1. OECD has identified [number to be inserted] PFHxS-related/precursor/polymer substances which all contain the fluorinated alkyl moiety C₆F₁₃SO₂⁻ (OECD, [pending publication of the report]) and a study published by the Norwegian Environment Agency identified 79 commercially available compounds including PFHxS and PFHxSF (Norwegian Environment Agency, 2017a, M-792/2017).
PFHxS is a strong acid with six fully fluorinated carbons, having both hydrophobic- and hydrophilic properties making it oil- and water-repellent (Kissa, 2001). Experimental data on the physicochemical properties of PFHxS are limited (Kim et al., 2015), however, some studies (Wang et al., 2011; Ding and Peijnenburg, 2013; Kim et al., 2015) have reported some empirical and estimated physicochemical properties of PFHxS and its related compounds.

Table 1 lists the chemical identity of PFHxS, and Table 2 lists selected modelled and experimental physico-chemical properties for PFHxS.

**Table 1. Chemical identity of PFHxS**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS number</td>
<td>355-46-4</td>
</tr>
<tr>
<td>IUPAC name</td>
<td>1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid</td>
</tr>
<tr>
<td>EC number</td>
<td>206-587-1</td>
</tr>
<tr>
<td>EC name</td>
<td>Perfluorohexane-1-sulphonic acid</td>
</tr>
<tr>
<td>Molecular formula</td>
<td>C₆F₁₃SO₃H</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>400.11</td>
</tr>
<tr>
<td>Synonyms</td>
<td>PFHxS</td>
</tr>
<tr>
<td></td>
<td>PFHxS</td>
</tr>
<tr>
<td></td>
<td>Perfluorohexanesulfonic acid</td>
</tr>
<tr>
<td></td>
<td>1,1,2,2,3,3,4,4,5,5,6,6,6-Tridecafluorohexane-1-sulfonic acid</td>
</tr>
<tr>
<td></td>
<td>Tridecafluorohexane-1-sulfonic acid</td>
</tr>
<tr>
<td></td>
<td>1-Hexanesulfonic acid, 1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluoro-</td>
</tr>
<tr>
<td></td>
<td>1,1,2,2,3,3,4,4,5,5,6,6,6-Tridecafluoro-1-hexanesulfonic acid</td>
</tr>
<tr>
<td></td>
<td>Tridecafluorohexanesulfonic acid</td>
</tr>
<tr>
<td>Trade names</td>
<td>RM70 (CAS No: 423-50-7), RM75 (3871-99-6), and RM570 (CAS No: 41997-13-1) (PFHxS-related substances produced by Miteni SpA, Italy). FC-95 Fluorad brand fluorochemical surfactant (CAS No: 3871-99-6). Contains PFHxS-K produced by 3M.</td>
</tr>
</tbody>
</table>
Table 2. Overview of selected physicochemical properties for PFHxS

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state at 20°C and 101.3 kPa</td>
<td>Solid white powder for PFHxS-K</td>
<td>As referenced in ECHA, 2017a (Company provided)</td>
</tr>
<tr>
<td>Melting point</td>
<td>320 K (41°C)</td>
<td>Kim et al., 2015</td>
</tr>
<tr>
<td>Boiling point</td>
<td>238–239°C</td>
<td>Kosswig, 2000 (measured)</td>
</tr>
<tr>
<td>pK_a</td>
<td>-3.45</td>
<td>Wang et al., 2011 (COSMOtherm)*</td>
</tr>
<tr>
<td></td>
<td>-3.3±0.5</td>
<td>ACD/Percepta 14.2.0 (Classic)</td>
</tr>
<tr>
<td></td>
<td>-5.8±1.3</td>
<td>ACD/Percepta 14.2.0 (GALAS)</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>58.9 Pa (0.0046 mmHg)</td>
<td>Wang et al., 2011 (COSMOtherm)*</td>
</tr>
<tr>
<td>Water solubility for PFHxSK</td>
<td>1.4 g/L (20–25°C)</td>
<td>Campbell et al., 2009 (measured)</td>
</tr>
<tr>
<td></td>
<td>2.3 g/L (non-dissociated)</td>
<td>Wang et al., 2011 (COSMOtherm)*</td>
</tr>
<tr>
<td>Air/water partition coefficient, K_{aw}</td>
<td>-2.38</td>
<td>Wang et al., 2011 (COSMOtherm)*</td>
</tr>
<tr>
<td>n-Octanol/water partition coefficient, K_{ow}</td>
<td>5.17</td>
<td>Wang et al., 2011 (COSMOtherm)*</td>
</tr>
<tr>
<td>Octanol-air partition coefficient K_{oa}</td>
<td>7.55</td>
<td>Wang et al., 2011 (COSMOtherm)*</td>
</tr>
<tr>
<td>Organic carbon/water partition coefficient K_{oc}</td>
<td>2.05, 2.40, 2.31 (range 1.8 – 2.76)</td>
<td>Guelfo and Higgins, 2013 (measured)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D’Augustino &amp; Mabury, 2017 (measured)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chen et al., 2018 field-based</td>
</tr>
</tbody>
</table>

* Estimates from Wang et al. (2011) refer to the neutral form of PFHxS only. It should be noted that PFHxS is present predominantly in its anionic form under environmental conditions due to its low pK_a. Therefore, to describe partitioning of both the neutral and ionized species of PFHxS in the environment, estimated partition coefficients of the neutral form need to be converted to respective distribution ratios, as suggested in Schwarzenbach et al. (2002) and Wang et al. (2011).

18. As discussed in ECHA 2017a, the experimental determination of partition coefficients is difficult because of the surface-active properties of the ionic PFSAs. The presence of ionic PFSAs depends on the dissociation of PFSAs in aqueous media. There are models available, i.e. COSMOtherm calculating partitioning coefficients of neutral PFAS. COSMOtherm is a quantum chemistry-based method that requires no specific calibration and is the method used in Wang et al., 2011. Therefore, COSMOtherm is expected to be able to estimate properties for PFSAs and PFCAs. Studies have shown that properties estimated with COSMOtherm showed good agreement with the experimental data for a number of PFAS (Arp et al., 2006; Wang et al., 2011).

1.2 Conclusion of the POPs Review Committee regarding Annex D information

19. The POPs Review Committee evaluated the proposal by Norway to list PFHxS, its salts and PFHxS-related compounds under the Convention as well as additional scientific information provided by members and observers at its thirteenth meeting. The committee concluded that PFHxS met the screening criteria specified in Annex D (decision POPRC-13/3). It was decided to review the proposal further and to prepare a draft risk profile in accordance with Annex E to the Convention and that issues related to the inclusion of PFHxS salts and PFHxS-related compounds that potentially degrade to PFHxS should be dealt with in developing the draft risk profile.

1.3 Data sources

20. The draft risk profile is based on the following data sources:

(a) The proposal to list perfluorohexane sulfonic acid (PFHxS), its salts and PFHxS-related compounds submitted by Norway (UNEP/POPS/POPRC.13/4);

(b) Information submitted by the following Parties and observers according to Annex E to the Convention: Australia, Canada, Denmark, Ecuador, Germany, Japan, Monaco, The Netherlands, Sweden, The United Kingdom, The United States, Alaska Community Action on Toxics and International POPs Elimination Network (ACAT/IPEN), Council of Chemists of the Province of Treviso, FluoroCouncil, Basel and Stockholm Conventions Regional Centre in China;
The supporting documents for the identification of PFHxS as a Substance of Very High Concern (SVHC) in the European Union prepared by Sweden, where PFHxS was recently identified as very persistent and very bioaccumulative (vPvB) (ECHA, 2017a, b);

Reports and other grey literature as well as information from peer-reviewed scientific journals;

The Australian National Industrial Chemicals Notification and Assessment Scheme (NICNAS) various tier II assessment for perfluoralkane sulfonates (C$_n$–C$_7$) (NICNAS, 2017a, b, c, d);


1.4 Status of the chemical under national regulations and international forums

21. In 2017, PFHxS and its salts were identified as Substances of Very High Concern (SVHC) and added to the REACH Candidate List due to their persistent and bioaccumulative properties (ECHA, 2017a). Inclusion on this list means the substances can be subject to further review and only used for specific authorized purposes under strictly controlled conditions. Moreover, upon request industry is obliged to inform consumers on the occurrence of the listed substances in consumer articles.

22. In Norway, PFHxS, its salts and PFHxS-related compounds was recently added to the national list of priority substances (Prioritetslista http://www.miljostatus.no/prioritetslisten) with a national goal to phase out the use within 2020. Some of the substances belonging to the PFHxS substance group (not PFHxSF or PFHxS) are listed on the Canadian Domestic Substances List (DSL) (Environment Canada, 2013), an inventory of substances manufactured in, imported into or used in Canada on a commercial scale. The DSL categorizes substances according to whether they are persistent and/or bioaccumulative and/or toxic. In the United States new uses of the chemicals in this group are prohibited without prior approval from the United States Environmental Protection Agency (US EPA) (United States Government, 2002; 2007). The US EPA published an action plan on long-chain PFAS, including PFHxS, and their salts and precursors in 2009. All chemicals were identified as persistent, bioaccumulative and toxic (US EPA, 2009). In Australia NICNAS has developed an action plan for assessment and management of chemicals which may degrade to PFCAs, PFASs, and similar chemicals. The primary assumption outlined in this action plan is that chemicals with a perfluorinated chain terminated by a sulfonyl group will degrade to the perfluoroalkyl sulfonate (of the same chain length) (NICNAS 2017, a, b, c or d).

23. Perfluorinated chemicals were identified under SAICM (Strategic Approach to International Chemicals Management) as emerging policy issue. Efforts are focused on gathering and exchanging information on perfluorinated chemicals and to support the transition to safer alternatives (http://www.saicm.org/EmergingPolicyIssues/Perfluorinatednbsp;Chemicals/tabid/5478/language/en-US/Default.aspx).

24. OECD provided a recent overview on risk reduction approaches for PFASs across countries (OECD, 2015). Responses from participating countries indicated that risk reduction approaches for PFASs are mainly covered under existing national and/or regional regulatory frameworks and cover principally long chain PFASs and their precursors and salts. The type of risk reduction approaches implemented across countries varies, but there is often a combination of voluntary and regulatory approaches that are used.

No harmonized classification or labelling is available for PFHxS in EU or globally. However, in Australia PFHxS-related compounds are included in the Inventory Multi-tiered Assessment and Prioritisation (IMAP) framework, which includes both human health and environmental assessments (NICNAS 2017c). In relation to human health risks, potassium PFHxSK, ammonium PFHxS, diethanolammonium PFHxS and PFHxSF were identified as: toxic if swallowed - Cat. 3 (H301), causes serious eye irritation - Cat. 2A (H319), causes damage to organs through prolonged or repeated exposure if swallowed - Cat. 1 (H372), suspected of causing cancer - Cat. 2 (H351).

2. Summary of the information relevant to the risks profile

2.1 Sources

2.1.1 Production, trade, stockpiles

25. As with PFOS, its salts and PFOS-related compounds, PFHxS, its salts and PFHxS-related compounds have been produced from a common parent compound, perfluoroalkane sulfonyl fluoride (PFHxSF). PFHxSF may be intentionally produced from the ECF of hexanesulfonyl chloride (C$_6$H$_{13}$SO$_2$Cl $+ 14$ HF $\rightarrow$ C$_6$F$_{13}$SO$_2$F $+ HCl +$ byproducts) with a yield of about 36% (Gramstad and Haszeldine, 1957).
26. In addition, PFHxSF may be unintentionally produced as a byproduct from the ECF of octanesulfonyl fluoride or chloride, the process to produce perfluoroocotane sulfonyl fluoride (POSF) (Gramstad and Haszeldine, 1957; Jiang et al., 2015). Unless manufacturers remove PFHxSF from POSF, it would stay in POSF and also react with reactants to form PFHxS, its salts and/or PFHxS-related compounds as byproducts in PFOS and its related compounds, as shown in, e.g., 3M, 2015; Herzke et al., 2012; Huang et al., 2015. It is likely that the ratios of PHxSF yields to POSF yields in the production of POSF are between 4% (Gramstad and Haszeldine, 1957) and 14.2% (reported by a Chinese manufacturer; Ren, 2016). This is supported by measured ratios of PFHxS to PFOS in commercial PFOS product, namely 3.5%–9.8% in 3M’s FC-95 (3M, 2015) and 11.2%–14.2% in three products from China (Jiang et al., 2015). Of the PFHxs impurities from the 3M ECF production process for PFOS also branched isomers of PFHxS were detected e.g. 18% branched from 4.7% PFHxS impurity in one lot (Benskin et al. 2010).

27. PFHxS and its salts may be produced after the hydrolysis of PFHxSF (Gramstad and Haszeldine, 1957). As with POSF (3M, 1999), PFHxSF may be further reacted with methyl- or ethylamine to form N-methyl or N-ethyl perfluorohexane sulfonamide (N-MeFHxSA or N-EtFHxSA), which may subsequently react with ethylene carbonate to yield N-methyl or N-ethyl perfluorohexane sulfonamide ethanols (N-MeFHxSE or N-EtFHxSE). N-MeFHxSA, N-EtFHxSA, N-MeFHxSE and N-EtFHxSE may be used as the building blocks of PFHxS-related compounds (3M, 1999).

28. The information on the production of PFHxS, its salts and PFHxS-related compounds is scarce in the public domain and mostly qualitative rather than quantitative. However, the substances are produced- and available on the world market and some of the substances (CAS Nos: 423-50-7; 355-46-4; 3871-99-6; 68259-08-5; 41997-13-1; 68259-15-4; 34455-03-3) are reported to the EU classification and labelling inventory (C & L Inventory, https://echa.europa.eu/information-on-chemicals) registration system, which shows that substances are produced, used and imported to the European market. Since the nomination of PFHxS, its salts and PFHxS-related compounds were nominated in May 2017, the number of notifications to the EU C&L inventory has increased. Furthermore, it is noted that PFHxS, its salts and many PFHxS-related compounds have been listed on multiple national chemical registration inventories (see UNEP/POPS/POPRC.14/INF/15; 3M, 2013, 2015 and 2018), indicating historical production, importation and/or uses of products containing these substances, historically and/or ongoing.

29. Historically, 3M was likely the biggest global manufacturer of PFHxS, its salts and PFHxS-related compounds, with an annual production of about 227 tonnes of PFHxSF in the US in 1997 (3M, 2000a); in 2000–2002, 3M ceased its production of PFHxS, its salts and PFHxS-related compounds (3M, 2000a). In addition, there may have been some (historical) production by Dainippon Ink and Chemicals in Japan (Dainippon, 1979, 1983a,b, 1985, 1986, 1988; Dainippon and Kawamura, 1981, 1983a,b,c). Further historical and/or current manufacturers of PFHxS, its salts and PFHxS-related compounds include at least Miteni from Italy (Miteni, 2018) as well as Hubei Hengxin (Hengxin, 2018), Wuhan Defu (Defu, 2018), Wuhan Yangtze River (Yangtze River, 2018), Wuhan Fengfan (Huang et al., 2015), Shanghai Vatten (Vatten, 2018; Huang et al., 2015) and Time Chemical (Time, 2018) from China According to Huang et al., 2010, as referenced in Wang et al., 2013, it was estimated that in the next 5 to 10 years production of surface treatment products containing PFHxSF- or perfluorobutansulfonyl fluoride (PFBSF)-derivatives will reach more than 1000 tonnes annually in China.

30. Using market research reports for PFHxS (CAS No: 355-46-4) and PFHxSF (CAS No: 423-50-7), review of peer-reviewed literature and other information sources in the public domain, and stakeholder consultations, the Norwegian Environment Agency (Report M-961/2018) performed a project to shed light on the sources to PFHxS in the environment. Information on the global production and use of PFHxS, its salts and related compounds and content in consumer products were collected. Across all evaluated sources of information as well as from consultation of stakeholders, it was found that there is a lack of publicly available information on the quantitative production levels and descriptions of product-specific uses of PFHxS and PFHxS-related compounds. There was also a lack of willingness from stakeholders to release such information. In addition, the quality of the market research reports is questionable and did not cover the global producers since only two producers in China were reflected in the reports.

31. Historical production or import of PFHxS, its salts and PFHxS-related compounds in the United States is extracted from the US EPA Inventory Updating Reporting Database and summarized in Table 3 below. In addition, an OECD survey in 2004 reported that <4000 kg of PFHxSF, <1500 kg of PFHxS, and <600 kg of FHxSA were produced in 2003 in Italy (OECD, 2005). Similarly, the subsequent two OECD surveys reported the production of some PFHxS, its salts and PFHxS-related compounds, but with no information on their respective production volumes and locations (OECD, 2006, 2010).
Metal plating recently developed and commercialized at least one new PFHxS-related amphoteric surfactant for foam fire-extinguisher (Vatten, 2018; Huang et al., 2015).

**AFFFs for firefighting**

34. Historically, 3M used PFHxS in the production of its AFFF formulations (Olsen et al., 2005). This is in accordance with patents from 3M (3M, 1972, 1973, 1992) and from another potential historical producer (Dainippon and Kamura, 1983; Dainippon, 1983b, 1985, 1986). In particular, 3M (1992) indicates that PFHxS-related compounds and PFOS were likely used in the same AFFF formulations, i.e. previously known as “PFOS-based AFFFs” (e.g. FC-600). This is in good agreement with measurements of legacy AFFF formulations (Vecitis et al., 2010; Herzke et al., 2012; Place et al., 2012; Houtz et al., 2013; Weiner et al., 2013; D’Agostino et al., 2014; Barzen-Hanson et al., 2017; Favreau et al., 2017). It is also well supported by measurements of environmental media at AFFF-impact sites (Backe et al., 2013; Houtz et al., 2013; Baduel et al., 2017; Barzen-Hanson et al., 2017; Bräunig et al., 2017; Lanza et al., 2017) and by measurements of firefighters’ serum levels (Jin et al., 2011; Rotander et al., 2015), where similar or higher levels of PFHxS than that of PFOS were detected, and in some cases, elevated levels of PFHxS-related compounds were identified. It is likely that such PFHxS-related compounds containing “PFOS-based AFFFs” have been discontinued after 3M ceased its global production in 2000–2002 (3M, 2000a). However, there may still be substantial stockpiles of such legacy AFFF formulations around the world (UN Environment, 2011; Zushi et al., 2017). Furthermore, Shanghai Vatten has recently developed and commercialized at least one new PFHxS-related amphoteric surfactant for foam fire-extinguisher (Vatten, 2018; Huang et al., 2015).

**Metal plating**

35. A number of patents (Dainippon, 1979, 1988; 3M, 1981; Hengxin, 2015) were identified, suggesting PFHxS, its salts and various PFHxS-related compounds may have been used in metal plating as mist suppressants. It is likely that at least Hubei Hengxin from China has marketed the potassium salt of PFHxS for metal plating (Hengxin, 2018). Furthermore, it should be noted that the manufacturing (including importing) or processing of one salt of PFHxS (tridecafluorohexanesulfonic acid, compound with 2,2’-iminodiethanol (1:1);
Historically, 3M used PFHxS-related compounds in some of its aftermarket (post-production) carpet protection products (Olsen et al., 2005), e.g., those carpet and upholstery protector containing FC-228 (ITEM, 2004). This is in accordance with the measured higher serum PFHxS concentrations (range 27.5–423 ng/mL) than that of PFOS (15.2–108 ng/mL), as well as highly elevated levels of PFHxS in household dust and carpets of a Canadian family, whose household carpets were treated 8 times with Scotchgard formulations over 15 years (Beesoon et al., 2012). It is likely such aftermarket carpet and upholstery protector products have been discontinued after 3M ceased its global production in 2000–2002 (3M, 2000a). However, it is reported that water-proofing textile finishes based on PFHxS-related compounds have recently been developed by at least Hubei Hengxin Chemical Co., Ltd. (CAS No: 68259-15-4, (tridecafluoro-N-methylhexanesulphonamide); CAS No: 68555-75-9 (tridecafluoro-N-(2-hydroxyethyl)-N-methylhexanesulphonamide); and CAS No: 67584-57-0, (2-[methyl](tridecafluoroethyl) sulphonyl)aminophenyl|amine|ethyl acrylate)) and Wuhan Fengfan Surface Engineering Co., Ltd. from China (Huang et al., 2015; Hengxin, 2018), as alternatives to PFOS-based compounds (Huang et al., 2015). The industrial activities with C-6 waterproofing agents for textiles in the Taihu Lake region in China might be a potential source of PFHxS where recent production and use of PFHxS as an alternative to PFOS and PFOA has been reported (Ma et al., 2017).

Polishing agents and cleaning/washing agents

One PFHxS-related compound (CAS No: 67584-53-6, [N-Ethyl-N-(tridecafluoroethyl) sulfonyl]glycine, potassium salt) was reportedly used in polishing agents and cleaning/washing agents at least between 2000 and 2015 in Denmark, Norway and Sweden with the use volumes claimed as confidential business information (SPIN, 2018). For example, the FCP102 Floor Sealer and FCP300 Duro Gloss Floor Sealer & Finish from Fritztile contain this compound (Fritztile, 2018a,b).

Coating and impregnation/prooﬁng

One PFHxS-related compound (CAS No: 67584-61-6, 2-[Methyl|(Tridecafluoroethyl) Sulphonyl]Amino|Ethyl Methacrylate) was reportedly used in impregnation/prooﬁng for protection from damp, fungus, etc. at least in four products between 2003 and 2009 in Denmark (SPIN, 2018).

Within the manufacturing of semiconductors

During the POPRC-13 meeting in 2017, an industry representative noted that PFHxS, its salts and PFHxS-related compounds are currently being used as replacements to PFOS, PFOA and their related compounds in the semiconductor industry. This information is further strengthened by published information that indicates that PFHxS is used in the semiconductor industry in Taiwan (Lin et al., 2010). PFHxS (133–330 ng/L), together with PFOs (128–670 ng/L), was one of the primary contaminants at a semiconductor fabrication plant waste water effluent site. Both PFSAs are present in the effluent in similar amounts showing that PFHxS is a primary substance in this process and are not unintentionally present at this site.

Other potential uses

Hubei Hengxin has marketed the potassium salt of PFHxS and PFHxS-related compounds (CAS No: 68259-15-4, tridecafluoro-N-methylhexanesulphonamide) for potential uses as a flame retardant and in pesticides, respectively (Hengxin, 2018).

2.1.3. Releases to the environment

To date, limited research has been conducted to specifically study the releases of PFHxS, its salts and PFHxS-related compounds in the environment, resulting in a lack of quantitative information on releases, although various studies have detected the ubiquitous presence of PFHxS in the environment (for details, see section Environmental levels and trends below). The occurrence of PFHxS and its related compounds in the environment is a result of anthropogenic production, use and disposal, since they are not naturally occurring substances. Unintentionally produced PFHxS, its salts and PFHxS-related compounds that are byproducts contained in PFOS, its salts and PFOS-related compounds are likely to have the same release pathways as the respective PFOS, its salts and PFOS-related compounds, which have been described in detail previously (3M, 2000b; UN Environment, 2006). This is in line with recent studies on source identification for PFHxS in groundwater samples (n=102) from non-industrial areas in China and drinking water in the U.S. (n=36977), showing that PFHxS clustered/occurred together with PFOS. Thus, for these sites, PFHxS may have originated from similar sources as PFOS such as AFFFs, pesticide applications, landfill leachates and WWTP effluents.
(Wei et al., 2018; Guelfo and Adamson et al., 2018). However, this was not the case in a study by Ma et al., (2018) where levels of PFHxS exceeded PFOS levels in Taihu Lake (Ma et al., 2018). This increase of PFHxS was linked to production and use of PFHxS as an alternative due to recent regulation of PFOS (and PFOA and related compounds) (Ma et al., 2018).

42. In addition, as with PFOA, PFOS and their related compounds (3M, 2000b; UN Environment, 2006, 2016), intentionally produced PFHxS and its related compounds may be released during their whole life cycle: they can be released at their production, at their assembly into a commercial product, during the distribution and industrial or consumer use, as well as from waste treatment facilities such as landfills and wastewater treatment plants (Shafique et al., 2017), including from land treatment using contaminated sludge from wastewater treatment plants. Studies indicate that PFHxS remain relatively unchanged throughout the successive treatment steps (Kunacheva et al., 2011, Thompson et al., 2011). Furthermore, PFHxS-related compounds may be transformed to PFHxS in the environment and biota (for details, see section on PFHxS precursors and degradation below).

43. Investigations revealed that PFHxS was the main PFAS constituent in the final waste effluent from a semiconductor fabrication plant and that the amount of waste effluent was estimated to be >5000 tonnes/day. The corresponding mass of PFHxS generated each day from the manufacturing process was estimated to be >0.67 kg (Lin et al., 2009). In the same study, raw waste effluent from an electronic/optoelectronic fabrication plant was analysed for content of PFASs. However, in this effluent the main constituent was PFOA, and PFHxS as found at low levels.

44. The contributions of individual stages to overall releases throughout the life cycle, and receiving environmental media, may vary across compounds and applications. In general, manufacturing processes constitute a major source of PFHxS, its salts and PFHxS-related compounds to the local environment, e.g., in elevated levels of PFHxS in water and the population close to a production plant in Minnesota, the US (Olai et al., 2012). In addition, some uses of PFHxS, its salts and PFHxS-related compounds may result in direct environmental releases. For example, the use of relevant AFFFs in fire-fighting training and real incidences, as well as accidental releases, contribute a substantial amount of PFHxS, its salts and PFHxS-related compounds in the environment (e.g., Backe et al., 2013; Houtz et al., 2013; Baduel et al., 2017; Barzen-Hanson et al., 2017; Bräunig et al., 2017; Lanza et al., 2017). In contrast, some other uses of PFHxS, its salts and PFHxS-related compounds may lead to releases to indoor environments such as from dust (Norwegian Environment Agency, Report M-806/2017c). One example is releases of PFHxS, its salts and PFHxS-related compounds from treated carpets to household dusts (Beesoon et al., 2012).

2.2. Environmental fate

2.2.1 Persistence

45. There are some characteristics which are valid for the whole group of PFASs, and therefore also for PFHxS; high electronegativity, low polarizability, and high bond energies make highly fluorinated alkanes extremely stable organic compounds. Based on the persistence of all other PFAS it can be assumed that PFHxS is persistent as well, and this was concluded in the EU when PFHxS was identified as very persistent and very bioaccumulative substance. This conclusion was made based on the knowledge of the stability of the C-F bonds and the read-across approach (ECHA, 2017c) with PFOS and PFOA (ECHA, 2017a, b).

46. PFASs are very resistant to chemical, thermal and biological degradation due to their strong C-F bonds (Kissa, 2001) and resistance to degradation makes them persistent in the environment. The stability of organic fluorine compounds has been described in detail (Siegemund et al., 2000 as referenced in ECHA, 2017a). When all valences of a carbon chain are saturated by fluorine, the carbon skeleton is twisted out of its plane in the form of a helix and this structure shields it from chemical attack. Several other properties of the carbon fluorine bond contribute to the fact that highly fluorinated alkanes are the most stable organic compounds. These include polarizability and high bond energies, which increase with increasing substitution by fluorine. The influence of fluorine is greatest in highly fluorinated and perfluorinated compounds (Siegemund et al., 2000 as referenced in ECHA, 2017a).

47. Experimental data on the persistence of PFHxS are very sparse. However, in a field study on photolysis of PFHxS in water conducted at high altitude in Mt. Mauna and Mt. Tateyama, no photolysis was observed for PFHxS following, respectively, 106 and 20.5 days of exposure (Taniyasu et al., 2013; Wang et al., 2015a).

48. PFHxS is found in soil, water and a variety of biota (see UNEP/POPS/POPRC.14/INF/[…]) in the vicinity of fire-fighting training areas following historical (and ongoing) use of PFHxS-containing foams (Braunig et al., 2017; Filipovic et al., 2015). Although no degradation studies were performed, results show that PFHxS is persistent and does not undergo significant abiotic or biotic degradation under normal environmental conditions after use of AFFF.
49. There are no available experimental biodegradation data in water or soil for PFHxS. Biodegradation of the structural analogue PFOS has been evaluated in a number of tests in several studies. Aerobic biodegradation has been tested in activated sewage sludge, sediment cultures and soil cultures (ECHA, 2017a). Anaerobic biodegradation has been tested in sewage sludge. PFOS did not in any of these tests show any sign of biodegradation (UNEP/POPS/POPRC.2/17/Add.5). The very Persistence (vP) classification (vP; persistence criteria under REACH (https://echa.europa.eu/documents/10162/13632/information_requirements_r11_en.pdf) are similar to the criteria for persistence in Annex D under the Stockholm Convention) of PFOA in water, sediment and soil has also been confirmed (ECHA, 2013). Furthermore, Quinete et al. (2010), demonstrated that PFBS is not biodegradable and expected to be a highly stable transformation product in which several precursors ultimately degrade into (Quinete et al. 2010; D’Agostino and Mabury, 2017; Wang et al., 2013). Since the stability of PFASs is in general based on the stability of the fluorinated carbon chain, it can also be concluded for PFHxS that no biodegradation can be expected in water, soil or sediment (ECHA, 2017a).

50. In Australian assessments, multiple studies conducted on a range of perfluorinated substances, including the C4 and C8 homologues of PFHxS, have found no evidence of potential for biodegradation, hydrolysis or aqueous photolysis under environmental conditions (NICNAS, 2017a; 2017b; 2017c).

51. Based on a read-across approach, conclusions applied to the persistence of as PFBS, PFOS and PFOA, it can be anticipated that PFHxS is not readily biodegradable. Thus, PFHxS is not expected to undergo hydrolysis or photolysis, and biodegradation and, like other PFASs, found to be poorly removed in waste water treatment plants (Danish Ministry of Environment, 2015). It can be assumed that PFHxS is not degradable and is very persistent in water soil and sediment (ECHA, 2017a).

2.2.2 Occurrence of PFHxS precursors and degradation

52. A theoretical assessment of abiotic degradation pathways to PFHxS has been performed (Norwegian Environment Agency, 2017a, M-792/2017). Based on available data on the degradation of PFBS- and PFOS-precursors, PFHxS precursors are anticipated to degrade to PFHxS in the environment. Results from this study indicated that substances containing the moiety C6F13SO2 may undergo abiotic degradation resulting in the release of PFHxS and C6 PFCA. However, comparing with PFOS degradation studies, one may expect that major products from abiotic degradation would rather be PFCA (PFHxA) than PFHxS (10:1), whereas major products from biotic degradation would be almost solely PFHxS (Wang et al., 2014, Norwegian Environment Agency, 2017a, M-792/2017).

53. Analytical methods for identifying and quantifying PFHxS-related compounds (e.g. perfluorohexane sulfonamides (FHxSA)) are at present very limited. Two studies using non-target analysis detected FHxSA in AFFF-impacted groundwater, 3M historical AFFF, and consumer products as well as in drinking water (Barzen-Hanson et al., 2017; Kabore et al. 2018). Although the data are not quantitative, they do show that PFHxS precursors have been used and that they are present in the environment and that human exposure can occur via drinking water. A recent study by D’Agostino and Mabury, 2017, reported that precursors of PFHxS are broadly present in urban- and AFFF-impacted Canadian surface waters. FHxSA was detected in surface water from sites with AFFF-impact and from sites without known FHxSA sources (D’Agostino and Mabury, 2017). FHxSA was found ubiquitously in all urban waters but at significantly lower levels than in AFFF-impacted waters. The study does not reveal whether the detected FHxSA was a result of direct use of FHxSA or indirect unintentional use due to contamination, but the authors conclude that precursors are present in Canadian urban- and AFFF-impacted surface water and that they so far have been rarely considered (D’Agostino and Mabury, 2017). However, FHxSA has previously been detected in AFFF as well as AFFF-impacted water, soil, and aquifer solids (Houtz et al., 2013; McGuire et al., 2014) and in tapwater from Canada, EU, Ivory Coast and China (Kabore et al., 2018).

54. A study from the north of Sweden showed that the concentration of PFHxS increased over a time-period of 1–14 days in a snowpack during seasonal melt. Furthermore, the PFHxS detected at different depths of the snowpack showed the highest concentration in the deepest layer (Codling et al., 2014). The reason for this increase during melting is unknown but one possible explanation is that PFHxS precursors transported through air precipitate locally and photodegrade to PFHxS during snowmelt (Codling et al., 2014). Meyer et al., 2011, also observed this phenomenon of enrichment in the melting snowpack of an urban watershed in Toronto, Canada. The fate of PFHxS and/or its precursors during snowpack ageing and the release during periods of melt could therefore influence their loading to both surface and ground waters. Furthermore, in a Dutch study, PFHxS was detected in infiltrated rainfall and the authors suggested that the presence of PFHxS could be due to degradation of precursors in the atmosphere (Eschauzier et al., 2010).

55. A variety of consumer products (e.g., textiles, paper, and carpets) and packaging containing PFASs and PFAS precursors are sent to municipal landfills at the end of their use life time. In a recent review, it was reported that PFASs are routinely detected in landfill leachate with PFASs (C4–C13) being most abundant, possibly an indication of their greater mobility, and reflecting the shift toward usage of shorter-chain substances
(Hamid et al., 2018). Furthermore, PFAS (C₈-C₂) substances are more easily released and prone to leach from landfills due to their higher water solubility and lower log Koc relative to longer-chain PFAS (Guelö & Higgins, 2013). Following disposal, PFASs are released from the waste through both biological and abiotic leaching either from precursor degradation (biological or abiotic) or from direct use of PFASs such as PFHxS or PFOS (Allred et al., 2015). In a study by Allred et al., 2014, several PFHxS precursors (FHxSAA, MeFHxSAA, EtFHxSAA) were detected in leachates from landfills indicating that these PFHxS precursors may be used in a variety of applications since the landfills had received residential and commercial waste, construction and demolition waste, biosolids from waste water treatment plants as well as non-hazardous industrial waste. A study of influent and effluent sewage water and sludge from waste water treatment plants found a net mass increase in PFHxS content between influent and effluent at 3 different waste water treatment plants in Sweden suggesting that degradation of precursor compounds during waste water treatment can be contributing to PFHxS contamination in the environment (Eriksson et al., 2017). Detection of PFHxS precursors is in line with what has been detected for precursors of PFBS and PFOS in other matrixes (see section 2.2.4; Stock et al., 2007; Del Vento et al., 2012; Dreyer et al., 2009).

56. Research on other PFASs indicates that PFHxS-related compounds may have the potential to degrade to PFHxS in the environment. Biodegradation data available for the C8N-ethylperfluorooctanesulfonamidoethyl alcohol (CAS No. 1691-99-2) demonstrate conversion to a carboxylic acid, with the ultimate biodegradation product being PFOS (Hekster et al., 2002; Martin, et al., 2010). Other chemicals containing the perfluorooctyl sulfonate group are expected to be susceptible to a similar biotransformation process (Martin, et al., 2010). Further, data available for the C4N-methylperfluorobutanesulfonamidoethyl alcohol (CAS No. 34454-97-2) indicate potential for atmospheric degradation to PFBS through oxidation by hydroxyl radicals (D’eon, et al., 2006; Martin, et al., 2010). Moreover, PFBS is expected to be a highly stable transformation product in which several precursors ultimately degrade into (Quinete et al. 2010; D’Agostino and Mabury, 2017; Wang et al., 2013; Norwegian Environment Agency, 2017a, M-792/2017).

2.2.3 Bioaccumulation and toxicokinetics

57. Due to the surface-active properties of PFHxS it is not possible to experimentally measure log Kow since the substance is expected to form multiple layers in an octanol-water mixture (OECD, 2002; 2006; Conder et al., 2008). In addition, PFHxS is relatively water soluble and has been shown to preferentially bind to proteins in liver and blood (Jones et al., 2003; Ahrens et al., 2009; Martin et al., 2003; Goeritz et al., 2013) and therefore the log Kow as descriptor for the bioaccumulation potential is not appropriate for PFHxS and related compounds. Furthermore, the reported BCF and BAF for PFHxS are below the numerical criteria of 5000, indicating a low bioaccumulation potential in aquatic organisms (Martin et al., 2003; Yeung and Mabury, 2013; Kwadijk et al., 2010; Casal et al., 2017; Ng and Hungerbuhler, 2014). The numerical criterion for BCF or BAF, which are based on considerations of lipid-partitioning substances, are not appropriate for PFHxS since PFHxS does not follow the behaviour of traditional hydrophobic compounds by partitioning into fatty tissues (UNEP/POPS/POPRC.3/INF/8/2003). As mentioned above, PFHxS preferentially binds to proteins in the organism and due to its water solubility is expected to quickly be excreted through gill permeation in gill-breathing organisms such as fish (Martin et al., 2003; Goeritz et al., 2013).

58. However, other factors such as high bioaccumulation in other species and monitoring data indicating a bioaccumulation potential of the chemical is sufficient to justify consideration of PFHxS within the Stockholm Convention. BMFs and TFMs explicitly account for biomagnification resulting from trophic transfer where the chemical concentration in one organism exceeds that of the organism at a lower level of the food chain (reviewed by Conder et al., 2012). As reviewed in the nomination dossier (UNEP/POPS/POPRC.13/4) a number of studies has reported BMFs over 1. Investigation of biomagnification in selected species from different Arctic regions, including the European- and Canadian Arctic, showed BMFs in the range 6.9 to 373 (Haukås et al., 2007; Butt et al., 2008). Furthermore, Houde et al., 2006, investigated the accumulation of PFHxS in the Bottlenose dolphins prey food web at two different locations in the United States and BMFs ranged from 1.8 to 14. In addition, in the SVHC dossier (ECHA, 2017a) authors have calculated from Riget et al., 2013, the BMFs for polar bear/ringed seal food chain to 16.7.

59. A study on pigs fed a diet contaminated with known concentrations of PFHxS, calculated dietary BMFs for whole pig, meat and liver for PFHxS were 20.1, 13.1 and 48, respectively (Numata et al., 2014).

60. An overview of the BMFs from the above-mentioned studies are shown in Table 4. Limitation of these BMF/TMF studies was discussed in the nomination dossier (UNEP/POPS/POPRC.13/4) and the SVHC dossier also reviews some of the bioaccumulation studies listed in Table 4 in detail (ECHA, 2017a).
Table 4. Available BMFs and TMFs from different food chains and diet studies

<table>
<thead>
<tr>
<th>Specie/Food web</th>
<th>Tissue</th>
<th>BMF</th>
<th>TMF</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bird/Fish (Arctic)</td>
<td>Liver</td>
<td>6.0–8.5</td>
<td></td>
<td>Haukås et al., 2007</td>
</tr>
<tr>
<td>Polar bear/Ringed seal (Arctic)</td>
<td>Liver</td>
<td>163–373</td>
<td></td>
<td>Butt et al., 2008</td>
</tr>
<tr>
<td>Dolphin/Fish</td>
<td>Plasma/whole</td>
<td>1.8–14</td>
<td>Dolphin 0.2 ± 0.9 (plasma)</td>
<td>Houde et al., 2006</td>
</tr>
<tr>
<td>Fish/Zoo plankton</td>
<td>Whole</td>
<td>9.1–10</td>
<td></td>
<td>Houde et al., 2006</td>
</tr>
<tr>
<td>Polar bear/Ringed seal (Arctic)</td>
<td>Liver</td>
<td>16.7</td>
<td></td>
<td>Riget et al., 2013</td>
</tr>
<tr>
<td>Fish/Chironomids (Lake fly)</td>
<td>Fillet/whole</td>
<td>1.43–4.70</td>
<td></td>
<td>(as reported in ECHA 2017a)</td>
</tr>
<tr>
<td>Pig diet study</td>
<td>Whole/meat/liver</td>
<td>13.1–48</td>
<td></td>
<td>Numata et al., 2014</td>
</tr>
<tr>
<td>Benthic</td>
<td>Whole</td>
<td>4.3</td>
<td></td>
<td>Munoz et al., 2017</td>
</tr>
<tr>
<td>Bentho-pelagic (demersal)</td>
<td>Whole</td>
<td>1.5</td>
<td></td>
<td>Munoz et al., 2017</td>
</tr>
</tbody>
</table>

61. Studies investigating trophic magnification of PFHxS in food webs are limited. TMFs were estimated, using both plasma-based and whole-body-estimate based calculations, in a marine food web (Houde et al., 2006). The reported TMFs ranged from 0.2 ± 0.9 to 0.1 ± 0.4. However, there are large variations in the TMFs, reflected in standard errors being larger than their corresponding TMFs. A number of factors such as temperature, time of sampling, reproduction status, migration, age and tissue versus whole body calculations may affect the calculation of TMF (Borgå et al., 2012; Franklin, 2016). In a recent study, two estuary intertwined sub-food web were investigated. TMFs for PFHxS were reported to be 4.3 for the benthic food web and 1.5 for the bentho-pelagic food web (Munoz et al., 2017; see Table 4 above).

62. The use of the elimination half-life is a useful addition to the use of BMF and TMF as an indicator of bioaccumulation potential that should be considered in a weight-of-evidence bioaccumulation assessment (Franklin, 2016). The reported half-life of PFHxS in humans varies between 5.3 and 35 years (Olsen et al., 2007; Fu et al., 2016; Li et al., 2018; Zhang et al., 2013; Section 2.3.2), which is the longest of all PFASs for which data are available. It is also comparable to the longest human elimination half-lives recorded for known PBT/vPvB- and POP-substances such as some PCBs (ECHA, 2017a). The elimination half-life of PFHxS, PFOS and PFOA in serum of 26 retired fluorochrome production workers has been reported (Olsen et al., 2007). Half-lives for PFHxS, PFOS and PFOA were 8.5, 5.4, and 3.8 years, respectively. Hence, the half-life of PFHxS is approximately 1.5 times longer than for PFOS. Elimination half-life in other species has also been reported (Sundstrom et al., 2012). However, pharmacokinetic studies in non-humans have demonstrated that serum elimination half-lives of PFHxS can vary considerably between species (Sundstrom et al., 2012; Numata et al., 2014) and, in some cases, between genders within species (Hundley et al., 2006; Sundstrom et al., 2012), but are generally much shorter than the reported human serum elimination half-lives. The species-specific and sex-specific elimination of PFHxS is highly expressed in the study by Sundstrom et al., 2012. Male and female rats were investigated in terms of serum elimination and results showed that females much more efficiently eliminated PFHxS than male rats. Furthermore, rats and mice appeared to be more effective at eliminating PFHxS than monkeys (Sundstrom et al., 2012). PFHxS is highly bound to plasma proteins (Kim et al., 2017; Jones et al., 2003) and pharmacokinetic studies have revealed that certain PFASs interact with proteins (e.g. albumin, liver fatty acid binding proteins, organic anion transporters) and that their clearance is species-, gender- and chain length-dependent (Andersen et al., 2008; Ng & Hungerbuhler, 2014).

63. The ability to strongly bind to blood proteins and the low clearance and slow excretion in the urine were recently proposed as the best predictors for a chemical’s bioaccumulation potential and long half-life (Tonnelier et al., 2012). In a study of pigs fed a diet contaminated with PFASs, PFHxS was found to have the slowest urinary excretion as well as the highest serum half-life among the investigated PFASs (Numata et al., 2014). In addition, blood plasma contained the largest amount of unexcreted PFHxS. Interestingly, studies on cows revealed a different pattern of PFHxS with regard to partitioning to blood, liver and edible tissues (Kowalcyzk et al., 2013). In dairy cows, muscle tissue contained the highest concentration of PFHxS indicating a lower tendency for PFHxS to accumulate in plasma than was seen for pigs (Numata et al., 2014). Furthermore, in the dairy cow study, PFHxS was detected in urine as well as milk during the experimental period showing a higher rate of elimination in cows than in pigs. These studies indicate that both elimination and tissue distribution is species-specific for PFHxS and other PFAS. It was later discussed whether ruminants such as cows have the possibility to biodegrade PFHxS and other PFAS by ruminal microorganisms in the rumen, but this study was inconclusive (Kowalcyzk et al., 2015).
16. The tissue distribution of PFHxS in humans is similar to what is observed in other mammals (e.g. Numata et al., 2014; Perez et al., 2013; Kowalczyk et al., 2013). In a Spanish human autopsy study PFHxS was found in all studied human (general public) organs/tissues: liver, kidneys, bone, brain and lungs, with highest levels observed in lungs and kidney, and was most frequently detected in lungs (43%) (Perez et al., 2013). The highest concentrations of PFHxS are found in blood, liver, kidney and lung. Transfer to breast milk appears to be a significant route of elimination during breastfeeding. Time-trend studies indicate that the human bioaccumulation potential of PFHxS may be larger than that of PFOS (ECHA, 2017a).

2.2.4 Potential for long-range transport

65. The potential for long-range transport of PFHxS was reviewed in the nomination dossier (UNEP/POPS/POPRC.13/4). In support of the long-range transport, data show that PFHxS is found in various environmental compartments in the remote regions of the Arctic including in air, sediment, snow, ice, soil, sediment and biota. In the Antartic PFHxS was found in biota and snow, strengthening the evidence that PFHxS can be transported over long distances far from the primary source (see UNEP/POPS/POPRC.14/INF/[…], Tables 1.1, 1.2 and 1.3 for biota and Table 1.4 for abiota).

66. While there is scientific consensus that PFASs are subject to long-range environmental transport, the pathway governing the long-range environmental transport of individual PFASs are dependent on the substance’s physiochemical properties (Butt et al., 2010; Ahrens et al., 2011; Rankin et al., 2016). Processes that transport PFHxS, its salts and PFHxS-related compounds to the Arctic include direct transport of compounds in air or water and/or indirect transport of neutral volatile precursor compounds that can undergo degradation by atmospheric oxidation or by biological degradation (Butt et al., 2010; Ahrens et al., 2011; Alava et al., 2015, Wang et al., 2015; Rauert et al., 2018). The PFHxS detected in environmental samples in remote regions may thus partially result from biological or abiotic degradation of such precursors prior to or after deposition (D’Eon et al., 2006; Xu et al., 2004; Tomy et al., 2004). Furthermore, local inputs from anthropogenic activities may be another source to PFHxS in the Arctic regions (reviewed in Butt et al., 2010).

67. Recent data from Svalbard indicate that levels of PFAS detected in polar bears are most likely not due to local sources, but is rather a result of global emissions. PFAS concentrations in polar bears were higher (30–35%) in animals that have a wider home range (offshore bears) than animals that live in coastal areas close to Svalbard (Tartu et al., 2018). Furthermore, using isotope analysis it was shown that polar bears with a wider home range eat more marine food than animals living close to the coast that have a large proportion of terrestrial food in their diet (Tartu et al., 2017b; 2018). In areas with more sea ice, such as those used by offshore bears, environmental PFAS levels were likely higher than in areas with less sea ice such as the coast of Svalbard. The positive relationship between PFHxS concentrations and home range longitude position in polar bears accords with a study that showed that PFHxS concentrations in ivory gull eggs from more eastern colonies at Franz Josef Land were slightly higher than concentrations in eggs from Svalbard (Miljeteig et al., 2009).

68. PFHxS is water soluble and transported through water to remote areas. Yamashita et al., 2005, first described global occurrence of PFHxS and other PFASs in open ocean water. Since then, a number of studies have reported frequent detection of PFHxS in open ocean and coastal water world-wide (reviewed in Butt et al., 2010; González-Gaya et al., 2014; Rosenberg et al., 2008; Busch et al., 2010; Benskin et al., 2012; Zhao et al., 2012; Ahrens et al., 2010; Wei et al., 2007; Bramovský et al., 2016). A number of studies reported the detection of PFHxS in Arctic seawater (Caliebe et al., 2005 as cited González-Gaya et al., 2014; Rosenberg et al., 2008; Busch et al., 2010; Cai et al., 2012; Benskin et al., 2012; Zhao et al., 2012; Yeung et al., 2017). In contrast, it has been suggested that oceanic long-range transport of PFHxS and other PFASs to the Antarctic has been more limited. Ocean currents and related dilution effects cause a decreasing concentration gradient from Northern Europe to the South Atlantic Ocean (Ahrens et al., 2010) explaining the lower concentrations detected in the Southern Ocean. Long distance from important source regions in the northern hemisphere, limited chemical manufacture of PFASs in the southern hemisphere, low effectiveness of delivery to the Antarctic via the atmospheric route and low yield of ionic PFASs produced from atmospheric oxidation are indicated as other possible explanations (Bengtsson Nash et al., 2010; Alava et al., 2015).

69. The higher frequency and levels of PFHxS detected in ocean waters compared to what has been detected in air, as well as its relatively high water solubility, gives an indication that the major transportation pathway for PFHxS to remote regions is through water currents (discussed in UNEP/POPS/POPRC.13/4). The ocean acts as a long-term reservoir of PFASs. Hence the input of PFHxS to the Arctic will likely continue over the long-term, particularly as the volume of Atlantic water masses transported northwards has increased during the last two decades (Hansen et al., 2015; Routti et al., 2017; UNEP/POPS/POPRC.13/4). In addition, Llorca et al., 2012, predicted that PFHxS, like most other perfluoroalkyl acids, is a “swimmer”, i.e., a chemical that is anticipated to undergo long-range environmental transport in water, by using the modelling result from Lohmann et al., 2007.

70. Due to detection of PFHxS in Arctic air and snow, long-range transport of PFHxS and/or PFHxS-related compounds through the atmosphere may occur (Theobald et al., 2007 as cited in Butt et al., 2010; Stock et al.,
A recent study reporting a significant increase in concentrations of PFHxS (p<0.006) during the period 2009 - 2015 in Arctic air both in Canada and Norway indicating that an increase in long-range transport has occurred (Rauert et al., 2018). Furthermore, higher PFHxS levels were detected in coastal water of Greenland compared to seawater, a finding that was attributed to precipitation in the form of rain, snow and/or ice melting at the Greenlandic mainland (Busch et al., 2010). An atmospheric source could involve neutral PFHxS related compounds as with those reported for PFBS and PFOS (Martin et al., 2006; D'Eon et al., 2006). A number of studies show evidence that PFAS precursors are transported through air and degrade to e.g. PFBS, PFOS (Stock et al., 2007; Dreyer et al., 2009; Del Vento et al., 2012) and most likely also PFHxS. This argument is strengthened by the detection of increasing amount of PFHxS during snow melt (Codling et al., 2014; Meyer et al., 2011) and detection of PFHxS in rain water (Eschauzier et al 2010). See section 2.2.2 for further details. The potential for PFHxS to undergo long-range environmental transport via air is further supported by the detection of PFHxS in lichen from the Antarctic Peninsula. Lichen accumulates pollutants from air and is used as bioindicators for air pollution (Augusto et al., 2013). PFHxS has also been detected in the feathers of an accipiter bird in rural areas of Tibet (Li et al., 2017).

Recent studies of polar bears from Norwegian Arctic showed that levels of PFSA (ΣPFSA₂; PFHxS and PFOS) were found in the highest concentration compared to other already regulated POPs. Total concentration (ng/g ww) of ΣPFSA₂ were 264.3±12.45 (PFHxS 30 ng/g ww; PFOS 233 ng/g ww), ΣPCB were 39.98±3.84 while ΣPBDE were 0.18±0.01 (Bourgeon et al., 2017; personal communication with Heli Routti). Hence in these studies the concentration of PFHxS is similar to the total PCB concentrations. In general, it is between 2–18 times more PFOS than PFHxS detected in animals from the Norwegian Arctic, on the other hand the amount of PFHxS is 2 – 7 times higher compared to PFOA (Miljeteig et al., 2009; Bytningsvik et al., 2012; Aas et al., 2014; Routti et al., 2017).

In summary, there is strong evidence that PFHxS is transported to remote regions through water and ocean currents and there is indication of long-range transport also through atmospheric transport of PFHxS and PFHxS-precursors.

2.3 Exposure

2.3.1 Environmental levels and trends

Environmental monitoring shows that PFHxS is ubiquitous in the environment. Numerous studies have reported detection of PFHxS in compartments such as surface water, deep-sea water, drinking water, wastewater treatment plant effluent, sediment, groundwater, soil, atmosphere, dust, biota, and humans globally (ECHA 2017a, annex II, Table 13; Tables 1.1–1.12 in UNEP/POPS/POPRC.14/INF/[…]).

The highest environmental levels of PFHxS measured are found in urban and/or industrial areas both in terms of biotic- and abiotic matrices (Gewurz et al., 2013; Ma et al., 2018). In China, PFHxS (ranging between 45.9–351 ng/L) was found to be the predominant PFAS in the water of Taihu Lake and its in-flow rivers (Ma et al., 2018). The rivers were considered the main input of PFHxS to the lake since some of the rivers mainly collect discharge water from bigger cities with local PFAS-related plants. The level of PFHxS in the lake has increased in the period 2009–2014 while levels of PFOA and PFOS have remained more or less the same, which may be an indication of increased direct use of PFHxS and/or PFHxS-related compounds (Ma et al., 2018).

Numerous studies have reported environmental contamination due to use of AFF based on fluorosurfactants (reviewed in Dauchy et al., 2017). PFHxS and/or PFHxS related compounds may be found in these foams either as an unintentional contamination due to the use of PFOS or as an intentionally added ingredient most likely in the form of perfluorohexane sulfonamide (FHxSA) (Barzen-Hanson et al., 2017; D’Agostino & Mabury, 2017). In Canada, PFHxS has been found in variety of matrixes including urban and rural surface water, air, Arctic ocean water and sediment (low frequency) at sites impacted- and not impacted by contamination from AFF (D’Agostino and Mabury 2017; Lescord et al., 2015; Wong et al., 2018; Genualdi et al., 2010; Gewurtz et al., 2013). PFHxS has been detected in ground- and surface waters close to airports and metal plating facilities, in surface water in the vicinity of waste water treatment plant, and in sludge and effluent/influent water from waste management facilities in Sweden (Ericson Jogsten and Yeung, 2017; Eriksson et al., 2017; Norwegian Environment Agency M-806, 2017c; Swedish EPA, 2016; Hu et al., 2016). In the Netherlands PFHxS (0.3 – 25 pg/L) has been detected in infiltrated rainwater likely originating from atmospheric transport of precursors (Eschauzier et al., 2010).

For a number of studies, exposure in limited areas (such as snowpack, melt water) can be attributed to long-range environmental transport (Zhao et al., 2012; Routti et al., 2017; Codling et al., 2014; Kwok et al., 2013; Yeung et al., 2017; Li et al., 2017). For example, PFHxS has been detected in snowpack in a remote area of northern Sweden (Codling et al., 2014), in surface- snow and water at Svalbard, Norway (Kwok et al., 2013)
and in marine Arctic and Antarctic surface waters (Zhao et al., 2012). In a study by Yeung et al., 2017, PFHxS was detected in Arctic snow/meltpond water as well as in ocean water.

77. Furthermore, recent studies report that PFHxS is the third most abundant PFAS in polar bears at Svalbard (Tartu et al., 2017a; Routti et al., 2017; Norwegian Environment Agency 2017d, M-817/2017). Similarly, for polar bears from Hudson Bay, Canada, PFHxS was second only to PFOS in concentration in the liver (Letcher et al., 2018). In plasma from polar bears at Svalbard (Norway), PFHxS levels were in the range 4.9–70 ng/g wet weight (ww) for the time period 2000-2014 (Routti et al., 2017). The concentrations in polar bears from Svalbard are similar to those reported for humans living at the proximity of a fluorochemical manufacturing plant in China (which in turn are an order of magnitude higher than in general populations in China) (Fu et al., 2015). Concentration of PFHxS in polar bears levelled off during the period 2003–2009, the levels increased towards the end of the time series (2014) with an average annual increase of 5%. However, the increase was not significant and with 95% probability the annual change varies between -1% per year to +11% per year (Routti et al., 2017 and personal communication with the author). Furthermore, the authors propose that the fast drop in PFAS concentration following the phase out of C₆₋₈ perfluoroalkyl sulfonates was due to decreased air transport of volatile precursors, while the recent increase in PFHxS levels is most likely due to the much slower oceanic transport of PFAS (Routti et al., 2017). However, a study of PFHxS levels in Norwegian Arctic air recently revealed that significant increasing amounts (<0.007 – 2.2 pg/m³; p<0.006) has been detected during the period 2009 – 2014 (Rauert et al., 2018) and these results correlate with the observed increase in polar bear levels described in Routti et al. 2017 above. In the Routti study, levels of PFHxS in liver from Arctic foxes collected during 1997-2014 were in the range <0.05–139 ng/g ww. PFHxS concentrations in Arctic foxes decreased 11% per year from 2002 to 2014, and the annual change with 95% probability was between -17% to -5%. PFHxS trends for both polar bears and Arctic foxes were similar prior and after they were corrected to the climate-related variation in feeding habits and food availability, the first reflecting the actual trends in the animals and the latter one reflecting the trends in their food web.

78. The results indicate that PFAS concentrations in polar bears and Arctic foxes are mainly affected by emissions. In a previous study, polar bears from five locations in the North American Arctic and two locations in the European Arctic as well as Greenland were studied and PFHxS was detected in polar bears at all locations (Smithwick et al., 2005a,b). At the Svalbard location in the European Arctic, a mean concentration of 2940 ng/g (range 2260–4430 ng/g wt) was detected in polar bear liver, which to our knowledge is the highest concentration of PFHxS reported in polar bears. In polar bears from East Greenland and in samples collected in 2006, a tissue distribution study showed that levels of PFHxS were highest in the liver followed by blood > brain = muscle ≈ adipose (Greaves et al., 2012), but consistently 2 orders of magnitude lower than PFOS. In a complementary study in various brain regions of the same polar bears, PFHxS concentrations were consistently the same throughout the brain (Greaves et al., 2013). Other studies have also detected PFHxS in marine mammals (Fair et al., 2012). See UNEP/POPS/POPRC.14/INF/[…] for additional data on exposure levels in remote- and other regions.

79. A number of studies have reported time-trends for PFHxS in various species and matrices. However, there are some discrepancies in these data and trends are both increasing (Routti et al., 2017; Holmstrom et al., 2010), decreasing (Lam et al., 2016; Huber et al., 2012), and without any significant trend (Ullah et al., 2014; Roos et al., 2013). In a systematic review of trend studies most data on PFHxS showed no significant change, while an increasing or decreasing trends were observed in a few matrices and regions (Land et al., 2018). However, as mentioned above the trend of PFHxS in polar bears in the European Arctic (Svalbard, Norway) is increasing (although non-significant within 95% of the confidence interval) in the time-period 2010 – 2014, while the trend in the Arctic fox from the same area is decreasing (Routti et al., 2017, and personal communication with the author). The increasing trend in polar bears (Routti et al., 2017) corresponds well with a recent study reporting increasing trends in Arctic air during the same time-period (Rauert et al., 2018). Hence, the temporal trend in each case is most likely dependent of emission sources, food choices (terrestrial, marine) and location (urban versus rural) among other factors.

2.3.2 Human exposure

80. Exposure pathways for PFAS, including PFHxS, include indoor dust, diet, drinking water and indoor/outdoor air (ECHA 2017a; Table 1.4 and 1.6 to 1.8 in UNEP/POPS/POPRC.14/INF/[…]). PFHxS, along with PFOS and PFOA, is the most frequently detected PFAS in blood-based samples from the general population world wide (ECHA 2017a, annex II, Table 14; Table 1.10 in UNEP/POPS/POPRC.14/INF/[…]) and present in the umbilical cord blood and breast milk (Kärman et al., 2007; Güzkow et al., 2012). PFHxS is transferred to the foetus through the placenta in humans and is excreted via lactation. Breast milk may therefore be an important source of exposure to breast-fed infants. Lifestyle factors contribute to the exposure; microwavable food intake and low frequency of indoor dust removal by vacuuming are connected to higher serum levels of PFHxS and other PFASs (Siebenaler et al., 2017).
81. A number of studies have reported presence of PFHxS in food items (EFSA 2012; Gebbink et al., 2015; Noorlander et al., 2011, Food Standards Australia New Zealand, 2016; Table 1.7 in UNEP/POPS/POPRC.14/INF[…]3). In a Swedish study, decreasing human dietary exposure in the period 1999–2010 from food stuff was observed (from 55 to 20 pg/kg bw/day), with egg and fish contributing most to human dietary exposure of PFHxS (Gebbink et al., 2015). In a Dutch study, crustaceans, lean fish, flour and butter (44, 23, 18 and 16 pg/g dw, respectively) had highest levels of PFHxS, low levels (<10 pg/g dw) were also found in fatty fish, industrial oil, bakery products and chicken (Noorlander et al., 2011). Levels of PFHxS in 2948 human food samples on the European marked quantified PFHxS in samples from vegetables (2%), fruits (21%), meat (1%), fish and other seafood (2%) and drinking water (12%) (EFSA, 2012). A study from Northern-Norway Mother-Child Contaminant Cohort Study (2007–2009) determined that high consumers of game had elevated levels of PFHxS with “a 20% difference between the highest and lowest intake group” (Berg et al., 2014). A study using data from the US National Health and Nutrition Examination Survey (NHANES) 2013–2014 for children aged 3–11 years-old (n=639) found that higher levels of PFHxS in serum were associated with consumption of fruits and juices (Jain 2018).

82. A study from Australia and New Zealand of PFHxS in food and water samples from contaminated sites, found highest PFHxS amounts in cattle meat (13.31 μg/kg), rabbit meat (4.94 μg/kg) and eggs (4.27 μg/kg). Other foods with high concentrations were crustaceans, fish liver and sheep meat and occasionally in some vegetables (e.g. spices, berries) (Food Standards Australia New Zealand, 2016).

83. It is estimated that drinking water consumption from sources near or in contaminated areas is one of the most important exposure pathways of PFAS for humans. Human biomonitoring studies concluded that exposure to PFHxS (and other PFAS) via drinking water can lead to much higher blood serum levels compared to unexposed groups, as observed in USA, Germany, Sweden and Italy (Hu et al., 2016; Wilhelm et al., 2009; Li et al., 2018; Annex E submission by Council of Chemists of the Province of Treviso, Italy). In Sweden exposure to PFHxS via drinking water lead to 180-times higher blood serum level compared to reference group (Li et al., 2018). Starting February 2014, the Swedish National Food Agency (NFA) conducted a survey of the drinking water in Sweden. The results indicate that just over one-third, or 3.6 million of the Swedish population, gets their drinking water from a water source that is affected by PFAS including PFHxS (Banzhaf et al., 2017). In 2010–2015, PFHxS was detected in drinking water in 23 US States among 134 water utilities serving 5.5 million people (EWG’s Tap Water Database). PFHxS was detected in more than 200 samples from >5000 public watersystems screened for PFAS in the USA (Guelfo and Adamson, 2018). Contamination of tapwater with PFHxS at low levels has been observed word wide (Mak et al 2009; Kabore et al., 2018; Zafeiraki et al., 2015; Boiteux et al., 2012; Ericson et al., 2009, see Table 1.6 in UNEP/POPS/POPRC.14/INF[…]3 for details).

84. Exposure may also occur via indoor air, mainly through particulate matter. In a Canadian household with carpets treated with ScotchgardTM regularly for the last 20 years, the carpet in the family room contained ~3000 ng/g PFHxS and blood levels in the family varied from 27.3–423 ng/mL, with the youngest child having the highest levels (Beeon et al., 2012). PFHxS has been detected in Norwegian homes and one office (Huber et al., 2011). Seven of eight analysed dust samples contained PFHxS at a median value of 1.4 ng/g, whereas the dust of the indoor environment in a Norwegian office contained approx. 30 ng/g. Dust from Belgian homes and offices were studied in D’Hollander et al., 2010, and reported median values of 0.1 and 0.2 ng/g respectively. A Canadian study (Kubwabo et al., 2005) shows a median of 23.1 ng/g in the indoor environment while 45.5 ng/g was detected in US homes and day care centres (Strynar and Lindstrom 2008). Recently, PFHxS levels in dust from a furniture centre and a hotel in Norway ranged from 1600 to 2300 ng/g. PFHxS was the predominant PFAS in the sample together with 6.2 diPAP, which was found at equally high levels in the range 330–3300 ng/g (Norwegian Environment Agency, Report M-806/2017c).

85. PFHxS has been detected in humans globally with high levels (1790 μg/L in blood serum) detected in people consuming PFHxS contaminated drinking water (Li et al., 2018). Levels in serum range from from <1–1790 μg/L, (ECHA 2017a, annex II, Table 14; Table 1.10 in UNEP/POPS/POPRC.14/INF[…]3). The PFHxS detection rate was above 98% in pregnant women in birth cohorts from Shanghai, Northern Norway, Greenland and two from Denmark (Bjerregaard-Olesen et al., 2017). PFHxS was detected in every sample of maternal and umbilical cord whole blood and plasma in a study of women and their newborn children (n=7) from Arctic Russia (Hanssen et al., 2013). A marked gender difference for elimination has been observed, with women aged between 15 and 50 years being more efficient than men in excreting PFHxS, with half-lives of 4.7 and 7.4 years, respectively (Li et al., 2018).

86. Furthermore, PFHxS was detected in umbilical cord blood (ECHA 2017a, annex II, Table 14; Table 1.11 in UNEP/POPS/POPRC.14/INF[…]3) and seems to be transmitted to the embryo to a larger extent than what was reported for PFOS (Kim et al., 2011; Günztkow et al., 2012; Pan et al., 2017). Cord serum albumin was a positive factor for higher transfer efficiency, while maternal plasma albumin was a negative factor (Pan et al., 2017).
Infants are also exposed to PFHxS through breast milk, however, PFHxS seems to be less efficiently transferred from mothers’ blood to breast milk compared to PFOS (Kim et al., 2011; Mogensen et al., 2015). However, after the first six months infants’ serum concentrations increased 4- to 3.5-fold for PFOS and PFHxS, respectively, in relation to cord blood (Fromme et al., 2010, Winkens et al. 2017). PFHxS was detected in more than 70% of breast milk samples analysed from Japan, Malaysia, Philippines, and Vietnam at mean concentrations ranging from 6.45 (Malaysia) to 15.8 (Philippines) pg/mL (Tao et al., 2008). Other studies report levels ranging from <0.005 to 0.3 μg/L (ECHA 2017a, annex II, Table 14; Table 1.12 in UNEP/POPS/POPRC.14/INF/[…]). Breastfeeding can be an efficient route of PFHxS elimination from the maternal blood. Comparisons of serum concentrations of women who did or did not breastfeed their infants showed that breastfeeding significantly decreases maternal serum concentrations of PFHxS, PFOS, and PFOA (Bjermo et al., 2013; Brandtsæter et al., 2013; Papadopoulou et al., 2015). Commonly a reduction of 3% in the mother’s serum for PFOS and PFOA and 1% for PFHxS per month of breastfeeding has been observed (Kim et al., 2011). In a Swedish monitoring study, PFHxS was analysed in breast milk samples from Stockholm and Gothenburg. In Stockholm, the concentrations of PFHxS, (low pg/mL range), have increased over the whole time-period (1972–2015), although if only considering the last 10 years there seemed to be a decrease during the last 10 years both in Stockholm and Gothenburg (Nyberg et al., 2017). PFHxS were detected in all 639 children age 3–11 from NHANES 2013–2014, at concentrations similar to those of NHANES 2013–2014 adolescents and adults, suggesting prevalent exposure to these PFAS or their precursors among U.S. population. This suggest prevalent exposure to PFHxS or its precursors among U.S. 3–11 years old children, most of whom were born after the phase out of PFOS in the United States in 2002 (Ye et al., 2018).

In a temporal trend study of different PFASs in serum of primiparous women in Uppsala, Sweden, there was a significant increase in PFHxS serum levels between 1996 and 2010 (8.3%/year) and with the concentrations in 2010 being approximately 6.5 ng/mL, reaching same level as PFOS (Glynn et al., 2012 and supporting info). It was later discovered to be due to drinking water contamination coming from historical use of AFFT at a closed military airport (Gyllenhammar et al., 2015). The levels of PFHxS in ground/drinking water varied from 16 ng/L (upstream of the airport) to 690 ng/L (downstream of the airport). The concentration in the communal water well was 83 ng/L.

In the area of Arnberg, Germany, there was a large environmental contamination incident of PFAS in 2006. Wilhelm and co-workers, 2009, evaluated the levels of some PFAS, including PFHxS, in human blood sampled before the contamination (during the period 1977–2004), and the PFHxS plasma levels had increased steadily (p<0.001) from 1977 to 2004. This was in contrast to PFOS and PFOA which remained fairly stable with a small increase during the first 10–15 years followed by a decrease from about 1990–1995. The total median concentration of PFHxS for the entire time period was 1.7 μg/L (range 0.5–4.6 μg/L).

In a recent human biomonitoring study in the city of Ronneby in Sweden people have been exposed to high levels of PFAS via drinking water, including PFHxS (1700 ng/L in 2013) from a nearby military airport. The levels of PFHxS were the highest ever reported in Sweden, (277 ng/mL, range 12–1600) (Li et al., 2018).

Increasing trend of PFHxS was also observed in archived serum samples from Norway (Haug et al., 2009); Serum levels in men (age 40–50 years) for PFHxS increased from 1976 to the early 1990s where the levels stabilised until 2006. The concentrations for PFHxS ranged from a minimum of 0.1 μg/L in 1977 to a maximum of 3.4 μg/L (2000) and the concentration was 1.4 μg/L in 2006. No temporal patterns were observed for PFHxS in archived serum samples from two German cities from 1980–2010 (Yeung et al., 2013), which is similar to observation from American Red Cross adult blood 2000–2010 (Olsen et al., 2012). No decline in PFHxS serum levels were observed in Californian women age 50–80 years in the period 2011 to 2015 in contrast to other PFAS which significantly declined (Hurley et al., 2018), this was also evident after removing participants with known drinking water exposure. In a longitudinal study of men conducted in Northern Norway, concentrations of PFOS and PFOA were highest during 1994–2001 and 2001, respectively, whereas PFHxS levels increased to 2001, however did not decrease between 2001 and 2007 (Nøst et al., 2014). In a study of blood spots from newborn in New York, USA from 1997 to 2007, PFHxS levels (and PFOS and PFOSA) increased and peaked around year 2000 and then declined. Levels of PFOS and PFOSA declined well below 1997 levels, but PFHxS levels were only slightly lower than 1997 levels (Spielhöff et al., 2008). In pooled human sera from the Australian population, PFHxS levels ranged from 1.2 to 5.7 ng/mL (08/09) and from 1.4 to 5.4 ng/mL (10/11) but overall the median levels of PFHxS have not significantly changed from 2002 (Toms et al., 2014). In a systematic review excluding data from occupational exposure and or populations exposed to point sources such as contaminated drinking water, the concentrations of PFOS, PFDS, and PFOA in humans are generally declining, and increasing concentrations of PFHxS have started to level off in recent years (Land et al., 2018).

Occupational exposure can lead to high serum levels of PFHxS. In firefighters’ serum levels of PFOS and PFHxS were in the range of 92–343 and 49–326 ng/mL, respectively (whereas the control group had 1–40 and 0.2–22 ng/mL of PFOS and PFHxS, respectively) (Rotander et al., 2015). PFNS, CL-PFOS, ketone-PFOS, ether-PFHxS and Cl-PFHxS were significantly more frequent in firefighters. At a Chinese fluorochrome
manufacturing plant for PFOS-related compounds, indoor dust (67.3%) and diet (31.6%) was found to be the largest sources to human PFHxS exposure (Gao et al., 2015). The drinking water PFHxS concentration was 0.78 ng/L in that study. In another study from a fluorochemical manufacturing plant in the same district, serum concentrations of PFHxS were in the range 12.8–10546 ng/mL, dust in residences connected to the plant had PFHxS in the range 0.44 to 706 ng/g, (while dust in the plant had PFHxS in the range 1481–257201 ng/g), diet PFHxS was in the range 0.067–0.448 ng/g ww and drinking water PFHxS from n.d to 3.2 ng/L (Fu et al., 2015). In the Fu et al., 2016, study serum concentrations of PFHxS were in the ranges of <LOD to 19,837 ng/mL (median=764 ng/mL). The serum levels of PFHxS in the exposed workers showed an obviously increasing trend with length of service. Concentrations in urine ranged from <LOD–77.1 ng/mL (median=1.7 ng/mL).

2.4 Hazard assessment for endpoint of concern

2.4.1 Toxicity to aquatic organisms and birds

93. Ecotoxicity data for PFHxS are limited, but available studies comparing toxic effects of PFBS and PFOS in aquatic organisms indicate that toxicity increases with increasing carbon length, and suggest a likelihood for adverse effects also in non-mammalian species (Giesy et al., 2010, Hagenaars, et al., 2011; Ulhaq, et al., 2013). Aquatic toxicity data are not available for PFHxS and PFHxS-related chemicals. The findings available for other perfluorinated acids indicate that the primary toxicity concern for these substances is chronic, intergenerational toxicity. Fish toxicity data available for the C8 homologue, PFOS, indicate potential for increased mortality in offspring when the parent generation is exposed to concentrations as low as 0.01 milligrams per litre (mg/L) (NICNAS, 2015c). PFBS was recently shown to induce multi-generational disruption of the thyroid system in marine medaka (Chen et al., 2018c). Exposure to PFBS (0, 1.0, 2.9 and 9.5 µg/L) was from F0 egg until sexual maturity, while F1 and F2 was not exposed. Reduced bodyweight was observed for both female and male F0 fish exposed to 2.9 µg/L and 9.5 µg/L, and plasma T3 level was marked reduced (41%) in the 9.5 µg/L group. In F1 eggs, an obvious but not significant reduction of T3 was observed, but in the F1 larvae a significant increase in T3 was observed in 1 µg/L group. Delayed hatching was coupled to elevated T3 levels in F1 larvae. Also, the F2 larvae TH disruption was exhibited with increased T4 levels (Chen et al., 2018c).

94. One recent study observed delayed development in northern leopard frog (Rana pipiens) tadpoles exposed to 10 µg/L PFHxS for 40 days. Although PFOS showed a higher BCF than PFHxS in this study, PFHxS was more potent for the endpoints (goosner stage (development) and snout-vent length) at day 40. This is the first study to show sublethal effects of PFHxS on amphibians at current environmental levels (Hoover et al., 2017). Another study on the African clawed frog (Xenopus laevis) tadpoles, indicates possible endocrine-disrupting potential of PFSA. Both PFOS and PFBS promoted expression of estrogen and androgen receptors in the brain, and estrogen receptor in the liver, from exposure levels of 0.1 µg/L for 2 months. Hepato-histology changes (hepatocyte degeneration and hepatocyte hypertrophy) was observed at high concentrations (100–1000 µg/L). PFOS at concentration at 1, 100 and 1000 µg/L induced degenerative spermatogonia while no such effect was observed for PFBS (Lou et al., 2013). (The PFOS used in this study was 98% pure, and detectable levels of PFHxS in range of 3.4–4.8 and 18.1–42.6 µg/L was observed in the water with PFOS 100 and 1000 µg/L, respectively).

95. PFOS is much more toxic to chironomids which live in sediment environments with low oxygen and where effects on haemoglobin are more relevant. Thus MacDonald et al., 2004, have concluded that PFOS toxicity thresholds for the chironomid Chironomus tentans are 2–3 orders of magnitude lower than those reported for other aquatic organisms. PFOS is also known to cause intergenerational toxicity to fish (Ji et al., 2008). No result for such studies are available for PFHxS but similar toxicity is quite possible.

96. Studies in birds have shown that PFHxS affects thyroid hormone pathways and genes related to neuronal development at 8.9 to 38,000 ng/g (Cassone et al., 2012 a,b; Vongphachan et al., 2011). Based on egg injection, the lowest observed effect concentration (LOEC) was 890 ng PFHxS/g ww for developing leghorn chicken embryos (Cassone et al., 2012b). Plasma T4 levels were reduced in a dose-dependent manner in embryos exposed to PFHxS from 8.9 ng/g, with statistically significant changes occurring at 890 ng/g (Cassone et al., 2012b). Furthermore, negative correlations between serum PFHxS and thyroid hormones T3 has been observed in Arctic birds (Nöst et al., 2014).

2.4.2 Toxicity in rodents relevant for humans

97. Experimental studies in rodents exposed to PFHxS consistently show adverse effects to the liver (Butenhoff et al., 2009; Bijland et al., 2011; Chang et al., 2018; Das et al., 2016), and associated metabolic effects, such as effects on serum levels of cholesterol, lipoproteins, triglycerides and free fatty acids (Butenhoff et al., 2009; Das et al., 2016; Bijland et al., 2011). Effects on the liver include a dose-dependent increase in hepatocellular hypertrophy associated with a significant enlargement of the liver (56% increase in male rats
following 42 days of exposure at 10 mg/kg bw/d (Butenhoff et al., 2009). In another study, 110% increase in liver weight was observed following 28 days of PFHxS exposure at 6 mg/kg/d in male mice (Bijland et al., 2011). The exposure caused hepatomegaly with steatosis as well as reduced serum total cholesterol and triglycerides. The authors hypothesize that the PFHxS-impaired lipoprotein secretion from the liver is the underlying mechanism, leading to accumulation of lipoproteins and triglycerides in the liver, causing hepatomegaly and steatosis and reduced serum lipoproteins and triglycerides (Bijland et al., 2011). In a reproductive/developmental toxicity study in mice, significantly increased liver weights were observed in F0 males and females from 1 mg/kg bw/day (Chang et al., 2018). At the highest dose, 3 mg/kg bw/day, the increased liver weight was associated with moderate to marked hepatocellular hypertrophy, steatosis, single-cell necrosis and increased alkaline phosphatase (ALP) as well as significantly reduced serum cholesterol. A LOAEL of 0.3 mg/kg bw/day based on reductions of total serum cholesterol at all doses was derived from the Butenhoff et al., 2009, as well as NOAELs of 0.3 mg/kg bw/d for effects on increased liver weight and hepatocellular hypertrophy.

98. The effect of PFHxS on the liver is believed to be, at least partly, mediated via activation of nuclear receptors. Several studies have explored the mechanistic effects of PFHxS on liver function, gene expression and peroxisome proliferator-activated receptor (PPAR)-alpha activation. In a study by Wolf et al., 2008, PFHxS was found to activate both mouse and human PPAR-alpha-receptor in vitro with LOECs of 8.76 and 4.38 µg/mL, respectively, (equals 10 and 5 µM). PFHxS also activated PPAR-alpha receptors from Baikal seals in a transactivation assay in a dose dependent manner (Ishibashi et al., 2011). In a study on wild type and PPAR-alpha null mice exposed orally to 10 mg/kg/d PFHxS for 7 days, liver effects (significant increase in liver weight, steatosis) was observed in both strains, whereas exposure to the PPAR-alpha agonist WY-14643 did not induce this effect in the PPAR-alpha null mice, indicating that the effects on the liver by PFHxS occurs also independent of PPAR-alpha (Das et al., 2017; Rosen et al., 2017). Gene expression profile also indicate that certain PFASs have the potential to activate constitutive activated receptor (CAR) and PPAR-gamma (Rosen et al., 2017). PFHxS also affected hepatic expression of genes involved in lipid and cholesterol metabolism in mice (Bijland et al., 2011; Das et al., 2017; Rosen et al., 2017). In a pre-adipocyte culture PFHxS was more potent than PFOS in inducing triglyceride accumulation, and both PFASs produced strong changes in gene expression with similarities to those observed with PPAR-gamma agonist (Watkins et al., 2015). In another study, PFHxS was found to rapidly inhibit gap junctional intercellular communication (GJIC) in a dose-dependent and reversible manner (Hu et al., 2002).

99. Exposure to PFHxS has also been shown to alter haematological parameters in male rats exposed for 42 days (Butenhoff et al., 2009). Hematocrit and red blood cell counts were significantly reduced at 3 mg/kg bw/d, haemoglobin concentration significantly reduced from the 1 mg/kg/d group and prothrombin time was altered at all doses tested. Changes in haematological parameters gave a LOAEL of 0.3 mg/kg bw per day (Butenhoff et al., 2009).

100. Thyroid organ toxicity has been observed following exposure to PFHxS. In a study on male rats exposed to PFHxS at 0, 0.1, 1.0, 3.0 or 10 mg/kg for 42 days, a dose-dependent increase in thyroid hypertrophy/hyperplasia of the follicular epithelium was observed (Butenhoff et al., 2009). The underlying mechanism for the thyroid effects were believed to be due to increased plasma turnover of thyroxine (T4) resulting in a stimulation in thyroid stimulating hormone (TSH) and a compensatory hypertrophy/hyperplasia. A LOAEL of 3 mg/kg bw/d was shown for hyperplasia of thyroid follicular epithelial cells. Some mechanistic studies have explored the effect of PFHxS on the thyroid hormone pathway. PFHxS competed with thyroxine (T4) for binding to the human thyroid hormone transport protein transthyretin (TTR) (Weiss et al., 2009; Ren et al., 2016), which is the main T4 carrier in cerebrospinal fluid, and expressed at high levels during prenatal and early postnatal life (Larsen and Delallo, 1989). PFHxS did also dose-dependently inhibit triiodothyronine (T3)-dependent cell growth in vitro from 10^-8 Molar (Long et al., 2013).

101. In a reproductive/developmental toxicity study in mice exposed to PFHxS at 0, 0.3, 1.0 or 3.0 mg/kg bw/day, significantly decreased litter size were observed from 1.0 mg/kg bw/day and reduced fertility index at 3.0 mg/kg bw/day (Chang et al., 2018). Adverse effect on reproductive or developmental parameters in dams or offspring in rats was not shown (Butenhoff et al., 2009, Ramhøj et al., 2018). However, a marked reduction in T4 was observed both in dams and offspring, with a significant reduction from 5 mg/kg/day, when dams were orally exposed from gestation day 7 (Ramhøj et al., 2018).

102. Adult dose-dependent behavior and cognitive disturbance was observed in mice after a single neonatal dose of PFHxS in the vulnerable brain developmental period (6.1 and 9.2 mg/kg bw, oral single dose at postnatal day 10) (Viberg et al., 2013). PFHxS affected the cholinergic system, manifested as altered nicotine-induced behavior in adult animals, which is in agreement with previous findings for PFOA and PFOS (Viberg et al., 2013). Levels of several proteins important in the brain growth spurt were affected 24 h after exposure, and taurine levels were different from control at 4 months in males (Lee and Viberg, 2013). In another study on developmental effects in rats, no effect on motoric activity was observed for rats exposed in utero and through lactation to 0.3–10 mg/kg/d (Butenhoff et al., 2009). However, the difference in elimination time between female
rats and mice (2 vs 30 days) may contribute to the diverging results on neurodevelopment effects observed between rats and mice.

103. Neurotoxic effects of PFHxS have been further explored, and PFHxS was found to reduce neuronal activity involved in learning and memory. PFHxS (100 µM) decreased the long-term potentiation in hippocampus CA1 region in adult rats with comparable potency as PFOS (Zhang et al., 2016). Furthermore, increased frequencies of spontaneous miniature postsynaptic currents as well as increased voltage dependent calcium influx were observed after exposure of hippocampal primary neuronal cultures to 100 µM PFHxS (Liao et al., 2009). PFHxS was also shown to induce apoptosis in vitro in the dopaminergic neuronal cell line (PC12) and glutamatergic primary cells (cerebellar granule cells). Doses tested corresponded to the Butenoff et al., 2009, in vivo study (0.3–10 mg/kg/d) which gave serum concentrations of 111–505 µM (Lee et al., 2014a, 2014b and 2016).

104. Endocrine disrupting activity has been observed for PFHxS in vitro. PFHxS inhibits 11β-dehydrogenase isozyme 2 (11b-HSD2) involved in corticosteroid hormone metabolism in human and rat kidney microsomes. The half-maximal inhibitory concentrations (IC50s) of human and rat 11b-HSD2 activities were 18.97 and 62.87 µM PFHxS, respectively (Zhao et al., 2011). PFHxS was shown to have anti-androgenic activity and weak estrogenic effect in vitro. PFHxS antagonize androgen induced androgen receptor (AR) transactivation in vitro (IC50=30 µM), and induced estrogen receptor (ER) transactivation between 10⁻³ and 10⁻⁴ M (20% of E2 activation). However, in co-exposure with E2 (25 PM), PFHxS further enhanced E2-induced ER response up to 187% (~similar enhancement was observed with PFOA and PFOS) (Kjeldsen and Bonefeld-Jorgensen 2013). PFHxS had weak inhibitory effect on aromatase activity (CYP19) IC50=298 µM (human placental carcinoma cells JEG-3) (Gorrochategui et al., 2014), and displace corticosterone hormone from serum binding proteins isolated from chicks and bald eagle (Jones et al., 2003).

105. The immunotoxic effect of PFHxS has not been investigated in controlled experiments. However, in an in vitro study, a range of related PFASs (PFBS, PFOS, perfluorooctane sulfonamide (PFOSA), PFOA, perfluorodecanoic acid (PFDA) and 8:2 fluorotelomer alcohol (8:2 FTOH)) showed immunosuppressive potential (Corsini et al., 2012), suggesting this might occur for PFHxS through the same mechanisms as observed for PFBS and PFOS.

2.4.3 Human epidemiology

106. Most epidemiology studies investigating the association between PFHxS levels and health effects are cross-sectional (measuring effect and exposure at the same time) with the limitations typical for those studies. Although the long half-life of PFHxS (5.3-35 years) increases the likelihood that current serum measurements represent past exposure that would be biologically relevant for the observed effect, there is likely to be some exposure misclassification. Prospective studies that evaluate effects in children relative to early childhood exposures could increase confidence in this body of evidence. The study design and covariates do also differ between the studies, and in some studies levels of PFHxS are highly correlated with other serum PFAS and thus weakening the results observed for PFHxS. An overview of outcome and study design from identified studies on serum lipids and thyroid effects are shown in Tables 3.1 and 3.2, respectively, in UNEP/POPS/POPRC.14/INF/[…].

107. Epidemiological studies have shown the association between serum levels of PFASs and PFHxS and serum levels of cholesterol, lipoproteins, triglycerides and free fatty acids (Fisher et al., 2013; Steenland et al., 2009; Starling et al., 2014). In a cross-sectional analysis of adults in Canada a significant association between PFHxS and cholesterol outcomes (total cholesterol (TC), low density lipoprotein cholesterol (LDL), TC/high density lipoprotein (HDL) ratio and non-HDL cholesterol were observed after weighting for sampling strategy (Fisher et al., 2013). No evidence to support the association between PFOA and PFOS with the cholesterol outcomes was observed. A positive monotonic increase in cholesterol with increasing decile of PFHxS, as well as for PFOA and PFOS, were observed in a study from the C3 Health project of a population living near a chemical plant (Steenland et al., 2009). However, Nelson et al., 2010 found a negative association with PFHxS and TC, non-HDL and LDL in the general US population (NHANES 2002-3), while positive associations were observed for PFOA, PFOS and PFNA. In pregnant women in Norway a positive association with HDL-cholesterol was observed for 5 PFAS including PFHxS (Starling et al., 2014). A study of pregnant women from the Spain found that PFOS and PFHxS were positively associated with impaired glucose tolerance and gestational diabetes mellitus (Matilla-Santander et al., 2017).

108. Effects on the thyroid hormone pathway have been shown for PFHxS in epidemiological studies. Levels of total T4 levels were found to increase with increasing PFHxS levels in the general U.S population, positive but non-significant associations was also seen with total T4, PFOS and PFOA (Jain, 2013). In another study of the same population higher serum levels of PFHxS were associated with increase in total T3 and total T4 in women (Wen et al., 2014). In men, a negative association was observed for serum PFHxS and free T4 of the U.S. general population (Wen et al., 2013). The authors also found that the risk of subclinical hyperthyroidism among
women increased with increased serum PFHxS (Wen et al., 2013). No causal link between serum PFHxS, PFOA or PFOS levels and the risk of hypothyroxinemia was observed in pregnant women in a case control study from Canada (Chan et al., 2011). In a retrospective birth cohort study in the Republic of Korea the association of certain PFAS and thyroid hormones in cord blood was explored. Gender-specific analysis showed that prenatal PFHxS exposure was positively associated with T3 in girls and PFOS was not associated with any thyroid-related parameter (Shah-Kulkarni et al., 2016). T4 level in male neonates were negatively correlated with increasing prenatal exposure to PFHxS in a birth cohort study from USA (Preston et al., 2018). Webster et al. (2016) used data from the general U.S population and found that two indicator stressors, thyroid-peroxidase antibody (TPOAb) and iodine status, did not modify the association between certain PFAS and TH alone. However, PFHxS and PFOS were negatively associated with free T4. In the small group with joint exposure to high TPOAb and low iodine, PFHxS, PFOA, PFOS and PFNA were positively associated with free T3, free T3/freeT4, TSH and TT3 (Webster et al., 2016). A systematic review of certain PFASs effects in pregnant women and children found some evidence of positive association of PFHxS and PFOS exposure and TSH levels in maternal blood, but no significant association with T3 and T4 (Ballesteros et al., 2017).

109. Human epidemiological studies have looked at the correlation between serum PFAS including, PFHxS and neurotoxic or neuro developmental effects in children. From the CrI-health project Stein and Stavitz (2011) examined the cross-sectional association in children (age 5–18 years; n=10,456) between serum PFOS, PFOA PFNA and PFHxS concentrations and parent or self-report of doctor-diagnosed ADHD with and without current ADHD medication. Although this population had highest exposure for PFOA, the strongest association between exposure and outcome was observed for PFHxS, with elevated odds ratio (OR) for quartiles 2–4 compared with the lowest quartile, ranging from 1.44 to 1.59 (PFHxS levels ranged from 0.25–276.4 ng/mL). No strong association with ADHD was observed with PFOS, PFOA and PFNA (Stein and Stavitz 2011). Significant increased odds for ADHD was also found in another study from U.S. using data from NHANES 1999–2000 and 2003–2004, with 1 ug/mL increase in PFHxS serum level, n=571 (Hoffman et al., 2010). However, in this study both PFOA, PFOS and PFNA were also positively associated with parental reported ADHD. In a study, investigating blood levels of various perfluoro- compounds in children and associations with behavioral inhibition, the results showed that blood levels of PFHxS were significantly associated with behavioral inhibition deficits in children (n=83) (Gump et al., 2011). High compared to low prenatal exposure to PFHxS was also associated with problematic behaviour using the Strength and Difficulties Questionnaire in a prospective study of children age 5–9 years from both Greenland and Ukraine (n=1023) (Hoyer et al., 2017).

110. Epidemiological studies indicate immunotoxic or modulatory effects caused by certain PFAS and PFHxS exposure prenatal and in childhood. The relationship between prenatal exposure to certain PFASs and prevalence of infectious diseases up to 4 years of life were investigated in 1558 mother-child pairs in Japan. Prenatal exposure to PFOS and PFHxS were found to be associated with occurrence of infectious diseases (such as otitis media, pneumonia, RS virus and varicella) in early life. For PFHxS the association was observed only among girls (OR: 1.55, (95% CI: 0.976, 2.45); p for trend=0.045) (Goudarzi et al., 2017). An inverse association was observed between maternal PFHxS serum levels and the level of anti-rubella antibodies (also observed for PFOA, PFOS and PFNA) and number of episodes of gastroenteritis at age 3 (also observed for PFOA) (Granum et al., 2013). Grandjean et al., 2012, observed odds ratios of 1.78 (95% CI: 1.08; 2.93) for inadequate antibody concentrations at age 7 for tetanus vaccine with doubling of the PFHxS serum concentration at age 5. In a follow-up study combining two birth cohorts from Faroe Island, 1997–2000 and 2007–2009, a significant reduction of pre-boost serum antibodies to tetanus vaccine at age 5 years was associated with doubling of serum concentrations at birth for PFHxS. A similar reduction was seen for PFOA (Grandjean et al., 2017). Furthermore, increased incidence of asthma has been indicated in children exposed to PFHxS (Dong et al., 2013; Zhu et al., 2016; Qin et al., 2017). In asthmatic children, a significant association between increasing PFHxS serum level and decreases in pulmonary function was observed (Qin et al., 2017). PFAS exposure at age 5 was associated with increased risk of asthma among a small subgroup of measles, mumps and rubella (MMR)-unvaccinated children. For the MMR vaccinated group a doubling of serum PFHxS at age 13 was associated with reduced odds of asthma at age 13 (Timmermann et al., 2017). A Canadian study of prenatal exposure to PFHxS and cord blood immune markers (IgE, IL-33, TSLP) reported no significant associations (Ashley-Martín et al., 2015). A prospective birth cohort study of 1056 woman found that prenatal exposure to PFOA, PFDA, PFDOA and PFHxS significantly increased the risk of childhood atopic dermatitis in female children during the first 24 months of life (Chen et al., 2018b).

111. Some studies indicate that PFHxS and certain PFAS might impact reproduction in humans. Both epidemiological and in vitro studies suggest that perfluoroalkyl acids might influence ovarian cell signalling and measures of overall reproductive health. In a recent study, blood and follicular fluid was collected from 36 subjects undergoing in vitro fertilization in the United States. Results showed that baseline follicle count was inversely related to plasma PFHxS concentrations, flagging this particular PFAS as a potential compound of interest in the context of ovarian pathology (McCoy et al., 2017). In a case control study from Denmark a strong significant association between serum certain PFAS levels (PFDA and PFNA) and miscarriage and an almost significant association with PFHxS was observed with adjusted odds ratio 1.53 (95% CI:0.99, 2.38) while no
association was observed for PFOA and PFOS (Jensen et al., 2016). In a birth cohort study from Canada between 2008–2011, n=1625, increased concentrations of PFOA and PFHxS in the female plasma were associated with decreased fecundability as measured by a longer time-to-pregnancy and increased odds of infertility, while no significant association was observed for PFOS (Velez et al., 2015).

112. In the U.S. population in NHANES 2009–2010 prevalence of osteoporosis was significantly higher in the high versus lowest quartiles of serum PFHxS with OR 13.2 (95% CI: 2.72–64.15), significant ORs were also observed for PFOA and PFNA (Khalil et al., 2016). In a case-control study of the relationship between serum levels of certain POPs and risk for breast cancer in Greenlandic Inuit women, Wielsøe et al. found a significant positive association between breast cancer risk and PFHxS (Wielsøe et al., 2017).

2.4.4 Mixture toxicity and combined effects of multiple stressors

113. Little is known about the mixture toxicity of PFASs at environmental relevant conditions, but some studies have investigated the mixture effects of the most commonly detected PFASs in human serum. More than additive effect was observed for a mixture of PFHxS, PFOS, PFOA, PFNA, and PFDA, when tested for anti-androgen activity in vitro at concentration corresponding to 1 μM of each single component in the mixture (Kjeldsen and Bonefeld-Jørgensen, 2013). Binary combinations of PFOA + either PFNA, PFHxA, PFOS or PFHxS tested for activation of PPAR-alpha in vitro produced concentration-response curves that were closely aligned with predicted curves for both response addition and concentration addition at low concentration (1–32 μM) (Wolf et al., 2014). A mixture of 10 PFAS (PFHxS included) at equimolar doses (final concentrations of each PFAS: 1.56–50 μM) acted in an additive manner when tested for transactivation of PPAR-alpha from baikal seal (Ishibashi et al., 2011). Viability studies of individual and mixtures of PFASs (C₂–C₁₁) had an obvious non-monotonic concentration-response relationship on human liver cells. Results of the three binary mixtures of PFASs, one with the combination PFHxS / S, showed that synergistic effects occurred under effective concentrations of IC0, IC10, and IC50 in mixtures while under IC-20 the synergistic effect only occurred under a higher proportion of PFSAs (Hu et al., 2014).

114. In a recent developmental toxicity study in rats, a more marked effect on serum T4 levels, antiandrogenic endpoints and liver weight were observed in the group co-exposed to PFHxS and an endocrine disruption mix (EDmix) than observed for PFHxS or EDMix alone indicating that PFHxS and the EDMix potentiate the effect of each other on various endpoints, despite their different modes of action (Ramhøj et al., 2018).

115. Polar bear studies from Greenland investigated the tissue distribution of PFASs; overall, PFASs and PFCAs concentrations were highest in liver followed by blood > brain > muscle ≈ adipose. For PFHxS, concentrations were by far the highest in liver (30.9 ± 2.1 ng/g) and blood (18.0 ± 1.1 ng/g), and concentrations in brain, muscle and adipose tissues were on similar levels (1.37 ± 0.10; 1.87 ± 0.1; 1.55 ± 0.20 ng/g) respectively. In the liver, PFHxS was found to be significantly higher in females (Greaves et al., 2012). Studies from East Greenlandic polar bears (n=10) found significant correlations between PFCAs and PFASs and neuro transmitter enzyme activity and neuro transmitter receptor density (Pedersen et al., 2015). Average brain sum PFAS was 28.8 ng/g ww, where PFOS accounted for 91% (PFHxS average 1.1 ng/g ww). Both PFCAs and PFASs showed negative association with density of muscarine acetylcholinesterase receptor. The cholinergic system was also affected in the mice study of Viberg et al., 2013. Furthermore, the concentrations of eleven steroid hormones were determined in eight brain regions, and levels could not be explained by concentrations in serum. Correlative analysis showed positive association between sum PFASs and 17-alpha-hydroxyprogrenenolone (OH-PRE) and several steroids were significantly correlated with the sum of PFCAs. The results indicate that an increase in the concentration of certain PFASs concurs with an increase in brain steroid hormones (Pedersen et al., 2016). These studies indicate that the concentration of certain PFASs in polar bears from East Greenland have exceeded the threshold limit for neuro-chemical and hormonal alterations (Pedersen et al., 2015; 2016). A recent study on polar bear from Svalbard found a negative relationship between certain PFAS (including PFHxS) serum levels and some thyroid hormones, and indicate that PFAS contribute to possible alteration of the thyroid hormone homeostasis in polar bears (Bourgeon et al., 2017). In a study of polar bear mothers and cubs from Svalbard, PFHxS levels did not decline between 1998 and 2008, with levels exceeding those associated with health effects in humans, including neurobehavioral effects and alterations in serum cholesterol (Bytingsvik et al., 2012).

116. There is evidence from experimental studies and indications from human epidemiology studies that PFHxS can affect lipid metabolism (see section 2.4.2 and 2.4.3). Tartu et al., 2017a, reported that diet and metabolic state were the main factors determining the amount of PFAS in female polar bears from Svalbard and that factors such as fasting affect the levels of PFHxS accumulated by female polar bears (Tartu et al., 2017a). In this study, levels of PFHxS were significantly negative related to urea: creatine ratios indicating a fasting state. Certain PFASs contribute to the multiple-stressor effects observed in polar bears from Svalbard. A recent study by Tartu et al., 2017b, showed that PFAS exposure was related to biomarkers of energy metabolism (lipid-related
genes, fatty acid synthesis and elongation in adipose tissue, and serum cholesterol, HDL and triglycerides). These effects were more pronounced when combined with reduced sea ice extent and thickness suggesting that climate driven sea ice decline and PFAS (and other organohalogenated compounds) have a synergistic negative effect on polar bears (Tartu et al., 2017b).

117. Arctic top predators such as polar bears are among the most polluted species in the world (Letcher et al., 2010) and undergo seasonal energy-demanding periods due to variation in temperature, food availability, reproduction and hibernation. As described in section 2.2.3, it is well known that certain PFASs will bioaccumulate in protein rich compartments (kidney, liver and blood etc) but it is not clear how body condition (such as starvation) affect tissue concentration and distribution of these PFASs and a possible alteration of the toxic potential. Cocktail effect due to increased concentration of traditional POPs in fat storage as well as climate changes will also affect these periods. PFHxS has high affinity to proteins and are not subject to biotransformation (Jones et al., 2003). In Arctic fox, adipose tissue was the only tissue affected by body condition, with lean foxes having three times (95% CI: 1.1, 12) higher concentrations of PFHxS than fat foxes (Aas et al., 2014). The large seasonal variability in fat content in Arctic mammals may thus affect tissue concentrations of certain PFASs and increase their potential effects during seasonal emaciation. The effects are not only related to the increased concentration of PFASs, but also to increased concentration of other POPs in target organs during decreased body condition which may further increase toxicity (discussed in Aas et al., 2014).

118. Cumulative limits for PFAS in drinking water and ground water have been set in Sweden and Denmark, when PFAS is believed to act together in a mixture. In Sweden, a concentration limit of 90 ng/L is set for PFAS11 (PFBS, PFHxS, PFOS, 6:2 FTS, PFBA, PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA9) and above this concentration risk reducing action is to be taken (https://www.livsmedelsverket.se/en/food-and-content/oonskade-ammen/miljojiffer/pfas-in-drinking-water-fish-risk-management#Action levels). A similar approach is enforced in Denmark (http://nst.dk/media/91517/pfas-administrative-graensevaerdier-27-april-2015-final.pdf). The United States (https://www.epa.gov/sites/production/files/2016-06/documents/drinkingwaterhealthadvisories_pfoa_pfos_updated_5.31.16.pdf) and Germany (https://www.umweltbundesamt.de/sites/default/files/medien/pdfs/pft/drinkwater-pfas.pdf) have made recommendations for content of PFOS and PFOA in drinking water. Furthermore, in the proposal for a new European Drinking Water Directive, which is under discussion, a limit value is proposed for the group of PFASs, as defined by the OECD. Values of 0.1 μg/L for individual PFAS and 0.5 μg/L for PFASs in total in as been suggested (http://ec.europa.eu/environment/water/water-drink/pdf/revised_drinking_water_directive_annex.pdf).

3. Synthesis of information

119. PFHxS, its salts and PFHxS-related compounds belongs to the PFAS group and has been used as surfactants, water- and stain protective coatings for carpets, paper, leather and textiles and in fire-fighting foams among other applications, often as a replacement for PFOS. It is also known that PFHxS are and have been unintentionally produced during the electrochemical fluorination processes used in production of other PFAS e.g. PFOS. These compounds have provided surfactant, water- and stain protective functions in various products due to their thermal stabilities and hydrophobic and lipophobic nature.

120. Information about current global manufacture of PFHxS, its salts and PFHxS-related compounds are limited. Historical production was mainly carried out by 3M and possibly also by some producers in Japan. One European manufacturer and a number of producers located in China have been identified, however, quantitative production data are not publically available. PFHxS, its salts and many PFHxS-related compounds have been listed on national chemical inventories (US, Canada, Japan, Australia, EU, Nordic countries and China) indicating historical/present production, importation and/or uses of products containing these substances. Possible direct and indirect sources of PFHxS to environmental releases are many and emissions may take place through air, dust, water, waste, wastewater and sludge.

121. While analytical methods for detection of PFHxS are well established, it is presently a challenge to qualify and analytically quantify PFHxS precursors due to the lack of established methods. However, precursors such as perfluorohexane sulfonamides were detected/identified in leachates from landfills indicating that these PFHxS precursors may be used in a variety of applications since the landfills had received waste from a number of sources. FHxSAs has also been detected in historical AFFF manufactured by 3M.

122. PFHxS has been detected in numerous matrixes worldwide including in the Arctic and Antarctica. Due to historical use of AFFF containing PFHxS and PFHxS-related compounds, high levels of PFHxS has been detected in the vicinity of fire-fighting training fields, both at commercial airports and at military facilities. Based on the persistence of PFAS in general, the known extreme stability of the C-F bonding and the monitoring data showing the ubiquitous presence of PFHxS in the environment, it is concluded that PFHxS is persistent to environmental- and biological degradation. Based on physical properties, PFHxS is known to undergo a protein bioaccumulation mechanism rather than lipid partitioning, which makes standard BCF/BAF analysis less
meaningful. Thus, comparable to PFOA and PFOS the use of log Kow and BCF have been demonstrated to be inappropriate measures of bioaccumulation. Several studies have reported bioaccumulation and biomagnification of PFHxS with field based BMFs and TMFs > 1 for different food chains, including from the Arctic. PFHxS binds strongly to proteins and this phenomenon is observed across species. The reported half-lives of PFHxS in human serum, which is known to be a good indicator of bioaccumulation, is very high (range 5.3–35 years).

123. PFHxS is found ubiquitously spread throughout the environment and in biota globally. A number of studies have reported exposure in remote areas that can be attributed to long-range environmental transport. PFHxS is detected in water, snow, air and biota at remote locations. Increasing trends, most likely due to increased emissions, have recently been detected in polar bears at Svalbard (Norway) and in air in the Canadian- and Norwegian Arctics. In polar bears, PFHxS was the third most abundant PFAS measured in the plasma of these animals. The main mechanism of transport to remote regions like the Arctic is presently most likely through ocean currents, supported by detection in a number of studies of PFHxS in waters worldwide. However, transport of PFHxS and PFHxS-related compound via the atmosphere cannot be excluded since PFHxS has been measured in snow, rainwater and air as well as in lichen. It is likely that both PFHxS and PFHxS-related compounds are transported through air to remote regions and that PFHxS-related compounds degraded to PFHxS locally.

124. Environmental trend data of PFHxS levels are not conclusive, in most regions and matrices no obvious trend has been observed, while a few matrices show a declining or increasing trend. Limited data are available on levels of PFHxS in humans in Asia where production continued after the 3M phase out.

125. Humans are exposed to PFHxS mainly through intake of food and drinking water but also through the indoor environment via exposure to dust or consumer products containing PFHxS or its precursors. Following PFOS and PFOA, PFHxS is the most frequently detected PFAS in blood-based samples from the general population worldwide. PFHxS is present in the umbilical cord blood and breast milk. Breast milk may be an important source of exposure to breast-fed infants since it is documented that PFHxS is excreted via lactation. Contamination of drinking water can result in highly increased PFHxS serum levels due to the long elimination-time in humans.

126. In rodents, liver effects such as increased liver weight, marked hepatocellular hypertrophy, steatosis and necrosis has been observed from PFHxS exposure. Effect on liver lipid and lipoprotein metabolism and altered serum cholesterol, triglycerides and lipoproteins has been observed in both rodents and humans. PFHxS activates peroxisome proliferating receptor (PPAR)-alpha, however, effects on liver are also observed in mice without PPAR-alpha, showing mechanisms of action independent of PPAR-alpha. In addition, effects on reproduction (decreased litter size and reduced fertility index) have been observed in mice following PFHxS exposure.

127. Neurotoxic and neurodevelopmental effects have been observed in controlled laboratory experiments in mice and rats, and some studies indicate association between behavioural inhibition in children and certain PFAS (and PFHxS) exposure prenatally and in childhood. Effects on the endocrine system, including in particular the thyroid hormone system have been reported cross-species (frog, bird, rat, polar bear and human). Furthermore, several epidemiology studies indicate that the naive and developing immune system might be vulnerable to certain PFAS and PFHxS exposure, observed as associations between serum PFHxS levels and reduced effect of vaccines and higher incidences of infections and asthma in children.

128. Certain PFASs, including PFHxS, contribute to the multiple-stressor effects observed in Arctic animals. Studies indicate that the level of certain PFAS in polar bear brain exceeded the threshold limit for neurochemical and hormonal alterations, and can affect the thyroid homeostasis. PFHxS bioaccumulate in protein-rich tissue, but during seasonal emaciation PFHxS also reach high levels in fat tissue. Combined exposure of PFASs with other POPs have unknown consequences and may case increased toxicity for heavily stressed species.

### Table 5. POP characteristics of PFHxS

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Meets the criterion (Yes/No)</th>
<th>Remarks</th>
</tr>
</thead>
</table>
| Persistence        | Yes                          | • No significant photolysis in water was observed for PFHxS following, respectively, 106 and 20.5 days of exposure in a field study of PFHxS conducted at high altitude in (Taniyasu et al., 2013).  
• PFHxS are found in soil, water and a variety of biota in the vicinity of fire-fighting training areas following the historical use of PFHxS-containing foams, showing that it is persistent and does not undergo any abiotic or biotic degradation under normal environmental conditions (Bräunig et al., 2017; Filipovic et al., 2015).  
• Read-across from experimental degradation data for PFBS, PFOS and PFOA |

27
<table>
<thead>
<tr>
<th>Criterion</th>
<th>Meets the criterion (Yes/No)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>demonstrate that these substances are very persistent (Quinet et al., 2010, ECHA 2017a; ECHA 2013), and based on the stability of organic fluorine compounds in general (Siegemund et al., 2000) one can expect that PFHxS have the same persistent characteristics.</strong></td>
</tr>
<tr>
<td>Bio-accumulation</td>
<td>Yes</td>
<td>• Found in elevated concentrations in top predators in the Arctic (Routti et al., 2017; Tartu et al., 2017b; Smithwick et al., 2005b).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Log K_{ow} is estimated to 5.17 and this is in line with estimated log K_{ow} for PFOS (Wang et al., 2011)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• BMFs&gt;1 in aquatic organisms (Haukás et al., 2007; Houde et al., 2006; Babut et al., 2017)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• BMFs &gt;1 in terrestrial organisms (Riget et al., 2013 as reported in ECHA 2017a).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• TMs&gt; 1 in aquatic organisms (Munoz et al., 2017).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Half-life of PFHxS in humans are the highest reported for any PFAS and varies between 5.3 and 35 years (Olsen et al., 2008; Fu et al., 2016; Li et al., 2018; Zhang et al., 2013)</td>
</tr>
<tr>
<td>Potential for Long-Range Environmental Transport</td>
<td>Yes</td>
<td>• PFHxS is found in air and snow in the Arctic (Theobald et al., 2007 as cited in Butt et al., 2010; Stock et al., 2007; Genuaidi et al., 2010, 2010; Butt et al., 2010; Wong et al., 2018; Norwegian Environment Agency M-757, 2017b, Rauert et al., 2018)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Detection of PFHxS in Arctic seawater (Caliebe et al., 2005 as cited González-Gaya et al., 2014; Rosenberg et al., 2008; Busch et al., 2010; Cai et al., 2012; Benskin et al., 2012; Zhao et al., 2012, Yeung et al., 2017).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Transport pathways are most likely both through water and air.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Transport of PFHxs-related compounds through air indicated by detection of increasing amounts of PFHxS in snowmelt (Codling et al., 2014; Meyer et al., 2011) and in rain water (Eschauzier et al., 2010).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Detection in top predators in Arctic with increasing levels far away from local sources (Routti et al., 2017; Tartu et al., 2017b; 2018).</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>Yes</td>
<td>PFHxS exerts effect on liver, serum lipids and cholesterol, and affect serum thyroid hormones and neuro development. Key data include:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Effect on liver; increased liver weight, marked hepatocellular hypertrophy, steatosis, necrosis and altered serum cholesterol, triglycerides and lipoproteins in rodents (Butenhoff et al., 2009; Bijland et al., 2011; Das et al., 2016, Chang et al., 2018). A LOAEL of 0.3 mg/kg bw/day based on reductions of total serum cholesterol at all doses was derived from the Butenhoff et al. (2009) as well as NOAELs of 0.3 mg/kg bw/d for effects on increased liver weight and hepatocellular hypertrophy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Effects on reproduction (decreased litter size and fertility index) was observed in mice from 1.0 mg/kg bw/day (Chang et al., 2018).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Epidemiology studies show association between PFHxS exposure level and serum concentration of cholesterol, lipoproteins (Fisher et al., 2013; Steenland et al., 2009).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Thyroid organ effects were observed in male rats exposed to PFHxS at 10 mg/kg for 42 days, a dose-dependent increase in thyroid hypertrophy/hyperplasia was observed (Butenhoff et al., 2009). Epidemiology studies show association between PFHxS serum levels and thyroid hormones (Jain 2013; Wen et al., 2013; Chan et al., 2011, Webster et al., 2016).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Correlation between serum levels of PFHxS and thyroid hormones has also been observed in field studies in Arctic birds (Nøst et al., 2013) and polar bears (Bourgeon et al., 2017).</td>
</tr>
<tr>
<td>Criterion</td>
<td>Meets the criterion (Yes/No)</td>
<td>Remarks</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>• Developmental neurotoxicity observed in mice (Viberg et al., 2013; Lee and Viberg, 2013). Epidemiological indications for cognitive developmental effects in humans (Stein and Stavitz 2011; Høyer et al., 2017).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Effect on the immunesystem has been shown in epidemiology studies, both reduced effects to vaccination (Granum et al., 2013; Grandjean et al., 2012; 2017), increased incidence of asthma (Dong et al., 2013; Zhu et al., 2016; Qin et al., 2017) and higher risk of infection in children has been observed in correlation with PFHxS serum levels (Goudarzi et al., 2017; Grannum et al., 2013).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Delayed development in northern leopard frog (Rana pipiens) tadpoles exposed to 10 μg/L PFHxS for 40 days (Hoover et al., 2017).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. **Concluding statement**

129. PFHxS is emitted into the environment from human activities e.g. from manufacturing processes, product use and disposal and management of waste. PFHxS is persistent, bioaccumulative and has the potential to undergo long-range environmental transport, making emissions of this substance a transboundary pollution problem including in remote areas. Globally, the occurrence and distribution of PFHxS is shown for humans, wildlife and the environment. Detections include measurements in the Arctic and Antarctic.

130. PFHxS is one of the most frequently detected PFAS in human blood in the general population and has a very long half-life in humans (range 5.3–35 years). Furthermore, PFHxS has been detected in human umbilical blood, serum and breast milk. High concentrations of PFHxS have been detected in soil, ground and drinking water near airports or fire-fighting training sites, sludge and wastewater from waste water treatment plants, as well as in the vicinity of PFAS/PFHxS production/usage plants and in leachate from landfills.

131. Available scientific literature suggests that there is a risk for adverse effects on the general population, in particular for children and population groups that are exposed to elevated levels of PFHxS and other PFASs through drinking water.

132. The concern for adverse effects relates to observed effects on the liver, thyroid hormone system, reproduction, as well as neurotoxic and neurodevelopmental effects has been shown. Furthermore, effects on lipid and lipoprotein metabolism add to the concern both for humans and Arctic animals.

133. Recent data from polar bear studies at Svalbard (Norway) revealed increasing levels of PFHxS in plasma. Furthermore, studies of polar bears have shown possible alteration in thyroid hormones due to exposure of some PFASs (including PFHxS). Delayed development in frog tadpoles exposed to PFHxS has also been observed. Altogether, these studies indicate that there is a risk for adverse effects in wildlife.

134. Based on the persistence, bioaccumulation, toxicity in mammals including humans and the widespread occurrence in environmental compartments including at remote regions, it is concluded that PFHxS, its salts and PFHxS related compounds are likely, as a result of their long-range environmental transport, to lead to significant adverse human health and environmental effects such that global action is warranted.
5. References


AMAP, 2017. AMAP Assessment 2016: Chemicals of Emerging Arctic Concern. Arctic Monitoring and Assessment Programme (AMAP), Oslo, Norway. xvi+353pp


32


ECHA (2013). Member State Committee support document for identification of Pentadecafluorooctanoic acid and its salts as substances of very high concern because of their CMR and PBT properties. Adopted on 14 June 2013.


34


Jain RB (2018). Contribution of diet and other factors to the observed levels of selected perfluorooalkyl acids in


Lanza HA, Cochran RS, Mudge JF, Olson AD, Blackwell BR; Maul JD, Salice CJ, Anderson TA (2017). Temporal monitoring of perfluorooctane sulfonate accumulation in aquatic biota downstream of historical aqueous film forming foam use areas. Environmental Toxicology and Chemistry 36(8), 2022-2029. DOI: 10.1002/etc.3726


Lin, AY, Panchangam, SC, Ciou PS (2010). High levels of perfluorocarboxylates in Taiwan’s wastewater treatment plants and downstream rivers pose great risk to local aquatic ecosystems. Chemosphere. 80(10):1167-74.


OEC(2010). Outcome of the 2009 Survey on the Production and Use of PFOS, PFAS, PFOA, PFCA, their Related Substances and Products/Mixtures Containing these Substances.


OEC(2005). Results of Survey on Production and Use of PFOS, PFAS and PFOA, Related Substances and Products/Mixtures Containing these Substances.


Tomy GT, Tittlemier SA, Palace VP, Budakowski WR, Braekevelt E, Brinkworth L, Friesen K (2004). Biotransformation of N-ethyl perfluorooctanesulfonamide by rainbow trout (Onchorhynchus mykiss) liver


